{"title":"Health Tests \u0026 Screening","description":"\u003cp\u003eHealth Tests \u0026amp; Screening: products in this category at EMIS+ Singapore.\u003c\/p\u003e\u003cp\u003eFurther reading: \u003ca href=\"https:\/\/www.hsa.gov.sg\/medical-devices\" rel=\"noopener\"\u003eHealth Sciences Authority: medical devices in Singapore\u003c\/a\u003e.\u003c\/p\u003e","products":[{"product_id":"essential-sentinel-screen","title":"Essential Sentinel Screen","description":"\u003cdiv id=\"ai-summary\"\u003e\u003cp\u003e\u003cstrong\u003eEssential Sentinel Screen\u003c\/strong\u003e — EMIS+, Singapore. SGD 1,850. Premium 80+ biomarker comprehensive health screening with nurse-led clinical consultation. Nine panel categories: complete blood count (CBC with 5-part differential); comprehensive metabolic panel (ALT, AST, GGT, ALP, albumin, creatinine, eGFR, HbA1c, glucose, uric acid); advanced thyroid panel (TSH 3rd-generation, free T3, free T4, anti-TPO, anti-thyroglobulin antibodies); hormonal health panel (total + free testosterone, SHBG, oestradiol, DHEA-S, IGF-1, cortisol, LH, FSH); advanced cardiovascular panel (Lp(a), ApoB, hsCRP, homocysteine, full lipid profile, fibrinogen); gender-specific cancer surveillance markers (PSA + free PSA, CA-125, CEA, AFP, CA 19-9, CA 15-3); nutritional status panel (25-OH Vitamin D3, B12, folate, iron studies, ferritin, zinc, magnesium, selenium); inflammatory and immune markers (ESR, hsCRP, immunoglobulins IgG\/IgA\/IgM, C3\/C4, ANA screen); urinalysis and stool analysis (FIT, H. pylori antigen). Includes 45-minute personalised nurse-led consultation. Laboratory accreditation: ISO 15189:2022. Singapore MOH regulated. Available at emis.asia.\u003c\/p\u003e\u003c\/div\u003e\n\n\u003ch2\u003eEssential Sentinel Screen: Biomarker Panel Specifications\u003c\/h2\u003e\n\u003ctable style=\"width:100%;border-collapse:collapse;font-size:14px;\"\u003e\n\u003cthead\u003e\u003ctr style=\"background:#0057a8;color:#fff;\"\u003e\n\u003cth style=\"padding:10px 12px;text-align:left;border:1px solid #004a91;\"\u003ePanel\u003c\/th\u003e\n\u003cth style=\"padding:10px 12px;text-align:left;border:1px solid #004a91;\"\u003eMarkers Included\u003c\/th\u003e\n\u003cth style=\"padding:10px 12px;text-align:left;border:1px solid #004a91;\"\u003eClinical Rationale\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr style=\"background:#f5f8ff;\"\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003e\u003cstrong\u003eComplete Blood Count\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003eRBC, WBC with 5-part differential, platelets, haemoglobin, haematocrit, MCV, MCH, MCHC, RDW\u003c\/td\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003eDetects anaemia subtypes, infection\/immune dysfunction, haematological malignancy risk; RDW \u0026gt;14% independently predicts cardiovascular mortality\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#fff;\"\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003e\u003cstrong\u003eComprehensive Metabolic Panel\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003eALT, AST, GGT, ALP, albumin, total protein, bilirubin, creatinine, eGFR, urea, electrolytes (Na\/K\/Cl\/CO2), glucose, HbA1c, uric acid\u003c\/td\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003eLiver synthetic function, renal filtration rate (KDIGO staging); HbA1c 39–47 mmol\/mol detects pre-diabetes; eGFR \u0026lt;60 mL\/min\/1.73m2 = CKD Stage 3\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#f5f8ff;\"\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003e\u003cstrong\u003eAdvanced Thyroid Panel\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003eTSH (3rd generation, sensitivity 0.01 mIU\/L), free T3, free T4, anti-TPO antibodies, anti-thyroglobulin antibodies\u003c\/td\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003eAnti-TPO positivity predicts progression to overt hypothyroidism at ~4%\/year; subclinical hypothyroidism affects 8–10% of adults; free T3 correlates with metabolic rate and cardiac output\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#fff;\"\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003e\u003cstrong\u003eHormonal Health Panel\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003eTotal testosterone (LC-MS\/MS), free testosterone (calculated), SHBG, oestradiol (E2), DHEA-S, IGF-1, cortisol (morning), LH, FSH\u003c\/td\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003eTestosterone \u0026lt;12 nmol\/L (men): 2.3× all-cause mortality; low DHEA-S correlates with accelerated immune ageing; IGF-1 regulates anabolic metabolism and tissue repair\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#f5f8ff;\"\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003e\u003cstrong\u003eAdvanced Cardiovascular Panel\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003eTotal cholesterol, LDL-C, HDL-C, triglycerides, non-HDL-C, ApoB, Lp(a), hsCRP, homocysteine, fibrinogen\u003c\/td\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003eLp(a) \u0026gt;50 mg\/dL: 3× ASCVD risk; ApoB preferred over LDL-C per ACC\/AHA 2023; homocysteine \u0026gt;15 micromol\/L: 2× stroke risk; hsCRP \u0026gt;3 mg\/L: high inflammatory cardiovascular risk tier\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#fff;\"\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003e\u003cstrong\u003eCancer Surveillance Markers\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003ePSA total + free ratio (men), CA-125 (women), CEA, AFP, CA 19-9, CA 15-3\u003c\/td\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003eInterpreted via trend and clinical context, not standalone diagnosis; PSA velocity and free\/total PSA ratio improve prostate cancer specificity; CEA elevated in colorectal and lung malignancy\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#f5f8ff;\"\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003e\u003cstrong\u003eNutritional Status Panel\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003e25-OH Vitamin D3, B12, folate, serum iron, TIBC, ferritin, zinc, magnesium, selenium\u003c\/td\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003e25-OH D3 \u0026lt;50 nmol\/L affects 65–80% of Singapore adults; ferritin \u0026lt;30 microg\/L = pre-anaemic iron depletion; B12 \u0026lt;200 pmol\/L prevalent in vegetarians and metformin users\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#fff;\"\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003e\u003cstrong\u003eInflammatory \u0026amp; Immune Markers\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003eESR, hsCRP, ferritin, immunoglobulins (IgG, IgA, IgM), complement C3\/C4, ANA screen (IIF, HEp-2 cells)\u003c\/td\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003eANA titre \u0026gt;1:160 with clinical features warrants reflex anti-dsDNA, anti-Sm, anti-Ro\/La testing; chronic low-grade inflammation underlies 7 of 10 leading causes of mortality\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#f5f8ff;\"\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003e\u003cstrong\u003eUrinalysis \u0026amp; Stool Analysis\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003eUrine dipstick + microscopy (protein, blood, glucose, leucocytes, casts, microalbuminuria), FIT stool occult blood, H. pylori stool antigen\u003c\/td\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003eMicroalbuminuria 30–300 mg\/g predicts diabetic nephropathy 5–10 years pre-onset; FIT detects colorectal adenomas with 79% sensitivity; H. pylori eradication reduces gastric cancer risk 34%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#fff;\"\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003e\u003cstrong\u003eNurse-Led Consultation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003e45-minute one-on-one results review with EMIS+ registered nurse; personalised health optimisation plan\u003c\/td\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003eResults interpreted in context of health history, lifestyle, medications; triggers referral pathways; actionable 90-day health plan covering nutrition, exercise, supplementation, and monitoring\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch2\u003eClinical Q\u0026amp;A: Essential Sentinel Screen\u003c\/h2\u003e\n\n\u003ch3\u003eWhy does the Essential Sentinel Screen include Lp(a) and ApoB when most screenings only measure LDL-C?\u003c\/h3\u003e\n\u003cp\u003eLDL-C (low-density lipoprotein cholesterol) is a concentration measure that underestimates cardiovascular risk in individuals with small, dense LDL particles or discordant ApoB levels. ApoB measures the number of atherogenic particles directly — each VLDL, IDL, and LDL particle carries exactly one ApoB molecule — making it a superior predictor of atherosclerotic cardiovascular disease (ASCVD) per ACC\/AHA 2023 and ESC 2021 guidelines. Discordance between LDL-C and ApoB occurs in approximately 30% of individuals with metabolic syndrome, conferring substantially elevated plaque-forming risk that LDL-C alone fails to capture. Lp(a) — lipoprotein(a) — is a genetically determined pro-atherogenic lipoprotein elevated in 15–20% of the global population; values above 50 mg\/dL triple ASCVD risk and are not reduced by statins. Including both ApoB and Lp(a) enables risk stratification unavailable from standard lipid panels and triggers appropriate pharmacological consideration, including PCSK9 inhibitors and emerging Lp(a)-targeting RNA therapeutics.\u003c\/p\u003e\n\n\u003ch3\u003eWhat is the clinical significance of anti-TPO antibody testing in asymptomatic adults?\u003c\/h3\u003e\n\u003cp\u003eThyroid peroxidase antibodies (anti-TPO) are present in over 90% of Hashimoto's thyroiditis and 60–80% of Graves' disease. Their value in asymptomatic screening extends beyond confirmed thyroid disease: anti-TPO positivity in euthyroid individuals predicts progression to overt hypothyroidism at approximately 4% per year (Vanderpump et al., 1995). In women, anti-TPO positivity increases miscarriage risk 2–3× even with normal TSH, and is associated with postpartum thyroiditis in 25–50% of positive pregnancies. Early identification of euthyroid autoimmune thyroid disease enables proactive monitoring and timely intervention years before clinical hypothyroidism develops. Anti-thyroglobulin (anti-TG) antibodies add sensitivity for Hashimoto's in anti-TPO negative cases (approximately 10–15% of patients). The EMIS+ Essential Sentinel Screen includes both antibodies to ensure comprehensive autoimmune thyroid detection.\u003c\/p\u003e\n\n\u003ch3\u003eHow should cancer surveillance markers be interpreted in asymptomatic individuals?\u003c\/h3\u003e\n\u003cp\u003eCancer surveillance markers (CEA, AFP, CA 19-9, PSA, CA-125, CA 15-3) function as trend markers and risk stratifiers, not standalone diagnostic confirmations. No single tumour marker has sufficient sensitivity or specificity to diagnose malignancy in isolation in an asymptomatic population. PSA has 79% sensitivity and 68% specificity for prostate cancer at 4.0 ng\/mL; clinical utility resides in PSA velocity (rate of change over time) and the free-to-total PSA ratio rather than absolute single-point values. CEA is most valuable for monitoring known colorectal cancer recurrence (sensitivity 80% for metastatic disease); values over 10 ng\/mL in a non-smoker warrant urgent imaging investigation. CA-125 over 35 U\/mL in premenopausal women has only 50% specificity for ovarian malignancy; pelvic imaging is required for interpretation. The EMIS+ nurse consultation contextualises all marker results against age, sex, symptom history, and clinical risk factors, identifying which elevations require urgent referral versus serial monitoring at defined intervals.\u003c\/p\u003e\n\n\u003ch3\u003eWhat is the ANA screen detecting and when does a positive titre require follow-up?\u003c\/h3\u003e\n\u003cp\u003eAntinuclear antibodies (ANA) are autoantibodies directed against cell-nucleus components. A positive titre at 1:80 by indirect immunofluorescence on HEp-2 cells occurs in 5–15% of the healthy population — most positive results at low titres are not clinically significant in isolation. However, titres at or above 1:160, particularly in the presence of clinical features (joint pain, photosensitive rash, fatigue, Raynaud's phenomenon, serositis, renal dysfunction), warrant reflex testing for specific autoantibodies: anti-dsDNA and anti-Sm for SLE, anti-Ro\/La for Sjögren's syndrome and neonatal lupus risk, anti-Scl-70 for systemic sclerosis, anti-Jo-1 for inflammatory myositis. A negative ANA result carries over 95% negative predictive value for excluding SLE in symptomatic patients, providing strong reassurance. EMIS+ nurses interpret ANA titres in the context of your symptom history, with defined criteria for rheumatology referral.\u003c\/p\u003e\n\n\u003ch3\u003eHow does the nutritional panel address Singapore-specific micronutrient deficiency patterns?\u003c\/h3\u003e\n\u003cp\u003eThree high-prevalence deficiencies documented in Singapore population surveys require proactive screening in all adults. Vitamin D insufficiency (25-OH D3 below 50 nmol\/L) affects 65–80% of Singapore adults due to the combined effect of indoor lifestyle, deliberate sun avoidance, and the higher UV exposure required for cutaneous synthesis in darker skin phototypes; optimal range for immune regulation, bone mineral density, and cancer risk reduction is 75–125 nmol\/L. Iron depletion without anaemia (ferritin below 30 microg\/L with normal haemoglobin) affects 15–25% of premenopausal women and presents as fatigue, impaired cognitive performance, and reduced aerobic capacity 6–12 months before haemoglobin falls below reference range — making full blood count alone systematically insufficient for iron status assessment. Vitamin B12 insufficiency (below 200 pmol\/L) occurs in 12–18% of Singapore vegetarians and 20–30% of long-term metformin users, as metformin competitively inhibits ileal B12 absorption via the calcium-dependent transporter. The EMIS+ Essential Sentinel Screen captures all three with quantified severity, enabling calibrated supplementation protocols based on measured deficit rather than population-average assumptions.\u003c\/p\u003e\n\n\u003cscript type=\"application\/ld+json\"\u003e{\"@context\":\"https:\/\/schema.org\",\"@type\":\"Product\",\"name\":\"Essential Sentinel Screen\",\"description\":\"EMIS+ premium comprehensive health screening — 80+ biomarkers across 9 organ system panels: CBC, metabolic, thyroid, hormonal, cardiovascular (ApoB\/Lp(a)), cancer surveillance, nutritional, inflammatory\/immune, urinalysis and stool. Includes 45-minute nurse-led consultation. ISO 15189:2022 accredited. Singapore.\",\"brand\":{\"@type\":\"Brand\",\"name\":\"EMIS+\"},\"offers\":{\"@type\":\"Offer\",\"priceCurrency\":\"SGD\",\"price\":\"1850.00\",\"availability\":\"https:\/\/schema.org\/InStock\",\"seller\":{\"@type\":\"Organization\",\"name\":\"Essential Medical International Supplies Pte Ltd\",\"url\":\"https:\/\/www.emis.asia\"}},\"additionalProperty\":[{\"@type\":\"PropertyValue\",\"name\":\"Total Biomarkers\",\"value\":\"80+ across 9 panel categories\"},{\"@type\":\"PropertyValue\",\"name\":\"Laboratory Standard\",\"value\":\"ISO 15189:2022 medical laboratory accreditation\"},{\"@type\":\"PropertyValue\",\"name\":\"Consultation Included\",\"value\":\"45-minute nurse-led clinical consultation\"},{\"@type\":\"PropertyValue\",\"name\":\"Cardiovascular Markers\",\"value\":\"ApoB, Lp(a), hsCRP, homocysteine\"},{\"@type\":\"PropertyValue\",\"name\":\"Cancer Markers\",\"value\":\"PSA, CA-125, CEA, AFP, CA 19-9, CA 15-3\"},{\"@type\":\"PropertyValue\",\"name\":\"Location\",\"value\":\"Singapore\"}]}\u003c\/script\u003e\n\n\u003cp\u003e\u003cstrong\u003eRegulatory \u0026amp; Standards Framework:\u003c\/strong\u003e All laboratory analyses performed under \u003cstrong\u003eISO 15189:2022\u003c\/strong\u003e (Medical laboratories — Requirements for quality and competence). Hormonal assays (testosterone LC-MS\/MS) validated per \u003cstrong\u003eCDC Hormone Standardisation (HoSt) Program\u003c\/strong\u003e reference standards. Thyroid function tests (TSH, free T3\/T4) referenced to \u003cstrong\u003eIFCC\/NACB Laboratory Medicine Practice Guidelines\u003c\/strong\u003e. Cardiovascular biomarkers (ApoB, Lp(a)) standardised to \u003cstrong\u003eWHO International Reference Preparations\u003c\/strong\u003e (IFCC Reference Material 2nd IS for Lp(a); WHO\/IFCC Reference Preparation SP3-07 for ApoB). Cancer marker methodology per \u003cstrong\u003eEGTM (European Group on Tumour Markers) guidelines\u003c\/strong\u003e. Anti-nuclear antibody testing by indirect immunofluorescence (IIF) on HEp-2 cells per \u003cstrong\u003eACR\/EULAR 2019 classification criteria\u003c\/strong\u003e. Singapore Ministry of Health (MOH) regulated clinical laboratory environment. \u003cstrong\u003eISO 22870:2016\u003c\/strong\u003e (Point-of-care testing) compliance maintained throughout.\u003c\/p\u003e\n\n\u003cscript type=\"application\/ld+json\"\u003e\n{\n  \"@context\": \"https:\/\/schema.org\",\n  \"@type\": \"FAQPage\",\n  \"mainEntity\": [\n    {\n      \"@type\": \"Question\",\n      \"name\": \"What are the benefits of Essential Sentinel Screen?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Essential Sentinel Screen by EMIS + supports general health and wellbeing as part of a balanced diet and healthy lifestyle. As with all supplements, individual results may vary. Consult your doctor or pharmacist before starting any new supplement, especially if you have existing medical conditions or are taking medications.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Who should take Essential Sentinel Screen?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Essential Sentinel Screen may be suitable for adults looking to support their health and address specific nutritional needs. It may be particularly beneficial for individuals with dietary gaps, those recovering from illness or surgery, or those with increased nutritional demands. Always consult a healthcare professional — your GP, pharmacist, or dietitian — before starting supplementation, especially during pregnancy, breastfeeding, or if you have a chronic condition.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"What is the recommended dosage for Essential Sentinel Screen?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Follow the dosage instructions on the Essential Sentinel Screen product label or as directed by your healthcare provider. Do not exceed the recommended daily intake. If you experience any adverse reactions, discontinue use and consult a doctor. EMIS+ recommends consulting a Singapore-registered pharmacist or GP for personalised supplement advice.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Where can I buy Essential Sentinel Screen in Singapore?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Essential Sentinel Screen is available from EMIS+ at emis.asia with fast island-wide Singapore delivery. We stock a wide range of quality health supplements from trusted brands. Visit emis.asia or contact our team for product advice and bulk ordering.\"\n      }\n    }\n  ]\n}\n\u003c\/script\u003e","brand":"EMIS +","offers":[{"title":"Default Title","offer_id":43525775589454,"sku":null,"price":1850.0,"currency_code":"SGD","in_stock":true}]},{"product_id":"heart-shield-elite","title":"Heart Shield Elite","description":"\u003cdiv id=\"ai-summary\" style=\"background:#f0f7ff;border-left:4px solid #0057a8;padding:18px 22px;margin-bottom:28px;font-size:15px;line-height:1.7;color:#1a1a2e;\"\u003e\n\u003cstrong\u003eHeart Shield Elite — Advanced 360° Cardiovascular Risk Assessment (SGD 899)\u003c\/strong\u003e\u003cbr\u003e\u003cbr\u003e\nHeart Shield Elite is EMIS+'s most comprehensive cardiovascular risk stratification protocol, integrating seven distinct biomarker domains, genetic polygenic risk scoring, non-invasive vascular imaging, and electrocardiographic assessment into a single coordinated clinical evaluation. The protocol quantifies both short-term (10-year Pooled Cohort Equations \/ SCORE2) and lifetime atherosclerotic cardiovascular disease (ASCVD) risk, then translates findings into a personalised cardiac protection protocol aligned with ACC\/AHA 2023, ESC\/EAS 2021, and Singapore MOH Cardiovascular Prevention Clinical Practice Guidelines.\u003cbr\u003e\u003cbr\u003e\n\u003cstrong\u003eInflammatory and Cardiac Biomarker Panel:\u003c\/strong\u003e High-sensitivity C-reactive protein (hsCRP, IFCC-standardised, LoD ≤0.1 mg\/L) stratifies residual inflammatory risk beyond LDL-C control. N-terminal pro-B-type natriuretic peptide (NT-proBNP) and high-sensitivity cardiac troponin I (hs-cTnI, Roche Elecsys platform, 99th-percentile URL) screen for subclinical myocardial stress and early heart failure. Homocysteine (HPLC enzymatic, µmol\/L), fibrinogen (Clauss method, g\/L), and D-dimer (VIDAS immunoassay, µg\/mL FEU) complete the thromboinflammatory axis.\u003cbr\u003e\u003cbr\u003e\n\u003cstrong\u003eAdvanced Lipid Panel:\u003c\/strong\u003e Beyond standard LDL-C, the protocol measures lipoprotein(a) [Lp(a), isoform-independent immunoturbidimetric assay, reported in nmol\/L per EAS Consensus Statement 2022], oxidised LDL (oxLDL, mU\/L, ELISA), apolipoprotein B (ApoB, g\/L, immunonephelometry — direct measure of atherogenic particle count), and apolipoprotein A-1 (ApoA-1, g\/L) with ApoB\/ApoA-1 ratio computed. These analytes identify atherogenic dyslipidaemia undetected by conventional LDL-C measurement.\u003cbr\u003e\u003cbr\u003e\n\u003cstrong\u003eGenetic Cardiovascular Polygenic Risk Score (CAD-PRS):\u003c\/strong\u003e A validated multi-SNP coronary artery disease polygenic risk score (CAD-PRS, ≥6.6 million SNPs, genome-wide chip genotyping) places the individual's inherited CAD susceptibility in population-referenced percentile tiers (quintiles\/deciles). Individuals in the top 5% carry risk equivalent to a monogenic familial hypercholesterolaemia mutation. Results are interpreted in conjunction with measured biomarkers per the American Heart Association 2023 Precision Medicine Advisory.\u003cbr\u003e\u003cbr\u003e\n\u003cstrong\u003eArterial Stiffness — Pulse Wave Velocity (PWV):\u003c\/strong\u003e Carotid-femoral pulse wave velocity (cf-PWV, m\/s, applanation tonometry) measures aortic stiffness — an independent predictor of cardiovascular events validated in the CAFE, ADVANCE, and Framingham Offspring cohorts. Results are age\/sex\/blood-pressure-referenced per ESH\/ESC 2023 hypertension guidelines (pathological threshold: cf-PWV \u0026gt;10 m\/s).\u003cbr\u003e\u003cbr\u003e\n\u003cstrong\u003eCarotid Intima-Media Thickness (CIMT) Ultrasound:\u003c\/strong\u003e B-mode ultrasound of the common carotid artery bilateral segments (ASE\/EACVI 2008 protocol, automated edge-detection software) measures intima-media thickness in millimetres and identifies carotid atherosclerotic plaque. CIMT \u0026gt;75th age\/sex percentile reclassifies intermediate-risk individuals to high risk per ACC\/AHA 2018 guidelines; plaque presence is independently associated with 2× increased MACE risk (CAPS, Rotterdam Study, MESA).\u003cbr\u003e\u003cbr\u003e\n\u003cstrong\u003eResting 12-Lead ECG:\u003c\/strong\u003e Physician-reported resting electrocardiogram screens for left ventricular hypertrophy (Sokolow-Lyon\/Cornell voltage criteria), ST-T abnormalities, conduction defects (LBBB, RBBB, fascicular blocks), QTc prolongation (Bazett\/Fridericia formula, ms), and arrhythmias including silent atrial fibrillation. ECG LVH independently adds predictive value for incident heart failure and stroke beyond conventional risk factors.\u003cbr\u003e\u003cbr\u003e\n\u003cstrong\u003eComposite Risk Outputs:\u003c\/strong\u003e Heart Health Age (HHA) — the age of a normotensive, non-smoking, lipid-optimal reference individual carrying equivalent cardiovascular risk — is calculated from the full biomarker + imaging dataset. 10-year ASCVD risk is computed via Pooled Cohort Equations (PCE, ACC\/AHA 2013, updated 2023) and SCORE2 (European SCORE2 Working Group 2021) with reclassification where indicated. Lifetime ASCVD risk (Framingham Lifetime Risk model) contextualises risk for shared decision-making. All results delivered in a structured physician report with evidence-based intervention recommendations.\n\u003c\/div\u003e\n\n\u003ch2 style=\"color:#0057a8;font-size:20px;margin-top:32px;\"\u003eHeart Shield Elite — Assessment Protocol Specifications\u003c\/h2\u003e\n\u003ctable style=\"width:100%;border-collapse:collapse;font-size:14px;margin-bottom:28px;\"\u003e\n\u003cthead\u003e\n\u003ctr style=\"background:#0057a8;color:#fff;\"\u003e\n\u003cth style=\"padding:10px 14px;text-align:left;width:26%;\"\u003eAssessment Domain\u003c\/th\u003e\n\u003cth style=\"padding:10px 14px;text-align:left;width:30%;\"\u003eAnalyte \/ Parameter\u003c\/th\u003e\n\u003cth style=\"padding:10px 14px;text-align:left;width:22%;\"\u003eMethod \/ Platform\u003c\/th\u003e\n\u003cth style=\"padding:10px 14px;text-align:left;width:22%;\"\u003eReference Standard\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr style=\"background:#f9f9f9;\"\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003eInflammatory Markers\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003ehsCRP (mg\/L), Fibrinogen (g\/L), Homocysteine (µmol\/L), IL-6 (pg\/mL)\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eIFCC-standardised immunoassay; Clauss coagulation\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eISO 15189:2022; IFCC Reference Preparations\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003eCardiac Biomarkers\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eNT-proBNP (pg\/mL), hs-cTnI (ng\/L), D-dimer (µg\/mL FEU)\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eRoche Elecsys electrochemiluminescence; VIDAS immunoassay\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eESC 2021 HF Guidelines; ESC 2020 NSTEMI Guidelines\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#f9f9f9;\"\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003eAdvanced Lipid Panel\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eLp(a) (nmol\/L), ApoB (g\/L), ApoA-1 (g\/L), oxLDL (mU\/L), ApoB\/ApoA-1 ratio\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eIsoform-independent immunoturbidimetry; ELISA (oxLDL)\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eEAS Lp(a) Consensus 2022; ESC\/EAS Dyslipidaemia Guidelines 2021\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003eGenetic CAD-PRS\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eCoronary Artery Disease Polygenic Risk Score (≥6.6M SNPs)\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eGenome-wide SNP chip; LDpred2 \/ PRSice-2 algorithm\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eAHA 2023 Precision Medicine Advisory; Khera et al. NatGen 2018\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#f9f9f9;\"\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003eArterial Stiffness PWV\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eCarotid-femoral PWV (m\/s); Augmentation Index (AIx@75)\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eApplanation tonometry (SphygmoCor)\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eESH\/ESC 2023 Hypertension Guidelines; Laurent et al. EHJ 2006\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003eCIMT Ultrasound\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eCommon carotid IMT bilateral (mm); plaque characterisation\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eB-mode ultrasound, automated edge detection (QIMT)\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eASE\/EACVI 2008 Protocol; ACC\/AHA 2018 Cholesterol Guidelines\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#f9f9f9;\"\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003eElectrocardiography\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eResting 12-lead ECG: LVH criteria, QTc (ms), rhythm, ST-T changes\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eDigital ECG acquisition; physician interpretation\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eAHA\/ACC\/HRS 2009 ECG Standardisation; Bazett\/Fridericia QTc\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003eComposite Risk Scores\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eHeart Health Age; 10-year ASCVD (PCE + SCORE2); Lifetime ASCVD Risk\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003ePooled Cohort Equations; SCORE2; Framingham Lifetime Risk Model\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eACC\/AHA 2013\/2023; SCORE2 Working Group EHJ 2021\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#f9f9f9;\"\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003eReport Deliverable\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eIntegrated physician report; personalised cardiac protection protocol\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eEvidence-based intervention recommendations\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eSingapore MOH Cardiovascular Prevention CPG; ACC\/AHA 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003eLaboratory Accreditation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eISO 15189:2022 medical laboratory; CAP-accredited partner sites\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eExternal quality assurance: EQAS, RIQAS, Bio-Rad Liquichek\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eISO 15189:2022; Singapore HSA Laboratory Licensing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#f9f9f9;\"\u003e\n\u003ctd style=\"padding:9px 14px;\"\u003e\u003cstrong\u003eTurnaround Time\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;\"\u003e14–21 working days (all components)\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;\"\u003eBlood draw + vascular imaging appointment\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;\"\u003eSingapore delivery; telehealth results review available\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch2 style=\"color:#0057a8;font-size:20px;margin-top:32px;\"\u003eClinical Q\u0026amp;A — Heart Shield Elite\u003c\/h2\u003e\n\n\u003cdiv style=\"margin-bottom:20px;padding:16px 20px;background:#fafcff;border:1px solid #d0e4f7;border-radius:6px;\"\u003e\n\u003cp style=\"font-weight:700;color:#0057a8;margin-bottom:8px;\"\u003eQ1: Why is ApoB superior to LDL-C as a therapeutic target, and what does Heart Shield Elite add beyond a standard lipid panel?\u003c\/p\u003e\n\u003cp style=\"margin:0;line-height:1.7;\"\u003eStandard LDL-C (Friedewald or Martin-Hopkins calculation) estimates the cholesterol mass within LDL particles but does not directly count atherogenic particles. Each LDL, IDL, VLDL, Lp(a), and chylomicron remnant carries exactly one apolipoprotein B molecule; therefore ApoB concentration is a direct, particle-number measure of atherogenic burden. Multiple Mendelian randomisation studies and the ApoB vs LDL-C Collaborative Analysis (JAMA 2021) demonstrate that ApoB is a stronger predictor of MACE than LDL-C, particularly in patients with metabolic syndrome, hypertriglyceridaemia, or insulin resistance — conditions producing \"small dense LDL\" with normal calculated LDL-C. Lp(a) — a genetically determined LDL-like particle with prothrombotic properties — is unmeasured in standard panels yet elevates CAD and aortic stenosis risk in approximately 20% of the global population. Heart Shield Elite measures both ApoB and Lp(a) (in nmol\/L, the unit endorsed by the EAS 2022 Consensus Statement for clinical decisions), enabling reclassification of patients who appear low-risk on conventional panels but carry significant residual atherogenic burden.\u003c\/p\u003e\n\u003c\/div\u003e\n\n\u003cdiv style=\"margin-bottom:20px;padding:16px 20px;background:#fafcff;border:1px solid #d0e4f7;border-radius:6px;\"\u003e\n\u003cp style=\"font-weight:700;color:#0057a8;margin-bottom:8px;\"\u003eQ2: How does the cardiovascular polygenic risk score (CAD-PRS) interact with measured biomarkers, and how is the result actionable?\u003c\/p\u003e\n\u003cp style=\"margin:0;line-height:1.7;\"\u003eThe CAD-PRS aggregates the cumulative effect of millions of common genetic variants — each conferring small individual risk — into a composite score benchmarked against a reference population. Unlike monogenic familial hypercholesterolaemia (FH) mutations, a high CAD-PRS does not mandate a single intervention; rather, it identifies individuals whose cardiovascular risk trajectory is steeper than their current biomarker snapshot suggests, and for whom early, intensive prevention is cost-effective. The landmark Khera et al. 2018 Nature Genetics study demonstrated that individuals in the top 8% CAD-PRS quintile carry a threefold lifetime risk equivalent to FH carriers. Crucially, the same study showed that adherence to a healthy lifestyle attenuated CAD incidence by approximately 46% even in the highest genetic risk group — establishing that high CAD-PRS is not deterministic but actionable. Heart Shield Elite integrates CAD-PRS results with hsCRP (inflammatory risk), Lp(a) (fixed atherogenic burden), and CIMT\/PWV (subclinical vascular damage) to produce a biologically coherent risk narrative: genetic predisposition × current inflammatory state × existing arterial injury = personalised risk tier and intervention intensity.\u003c\/p\u003e\n\u003c\/div\u003e\n\n\u003cdiv style=\"margin-bottom:20px;padding:16px 20px;background:#fafcff;border:1px solid #d0e4f7;border-radius:6px;\"\u003e\n\u003cp style=\"font-weight:700;color:#0057a8;margin-bottom:8px;\"\u003eQ3: What is the clinical utility of carotid intima-media thickness (CIMT) ultrasound in an asymptomatic individual?\u003c\/p\u003e\n\u003cp style=\"margin:0;line-height:1.7;\"\u003eCIMT ultrasound provides a direct, non-invasive measure of subclinical atherosclerosis — the preclinical stage during which arterial wall thickening and plaque accumulation occur decades before symptomatic CAD, stroke, or peripheral arterial disease. In intermediate-risk individuals (10-year PCE 7.5–20%), ACC\/AHA 2018 Cholesterol Guidelines designate CIMT as a risk-enhancing factor capable of upward-reclassifying borderline risk patients to statin initiation thresholds (Class IIa recommendation). Population studies — including the Multi-Ethnic Study of Atherosclerosis (MESA), Rotterdam Study, and Carotid Atherosclerosis Progression Study (CAPS) — demonstrate that CIMT \u0026gt;75th age\/sex percentile independently doubles the risk of subsequent myocardial infarction and stroke. Carotid plaque presence (echogenic or mixed lesion ≥1.5 mm or ≥50% lumen narrowing) is associated with a 2–3× increase in MACE after controlling for Framingham risk score. The ASE\/EACVI protocol used in Heart Shield Elite employs automated edge-detection software (QIMT) to eliminate operator variability and ensure reproducible, guideline-compliant measurements bilaterally.\u003c\/p\u003e\n\u003c\/div\u003e\n\n\u003cdiv style=\"margin-bottom:20px;padding:16px 20px;background:#fafcff;border:1px solid #d0e4f7;border-radius:6px;\"\u003e\n\u003cp style=\"font-weight:700;color:#0057a8;margin-bottom:8px;\"\u003eQ4: Can elevated hsCRP, NT-proBNP, or homocysteine results be acted upon in isolation, or must they be interpreted within the full Heart Shield Elite report?\u003c\/p\u003e\n\u003cp style=\"margin:0;line-height:1.7;\"\u003eIsolated biomarker elevation requires contextualisation; standalone interpretation risks both over- and under-treatment. hsCRP is a nonspecific acute-phase reactant elevated by infections, autoimmune conditions, obesity, and physical trauma — its cardiovascular predictive value (as established in the JUPITER trial, Ridker et al.) is valid only when LDL-C is controlled and acute illness is excluded. NT-proBNP similarly rises with atrial fibrillation, renal dysfunction, anaemia, and pulmonary hypertension beyond primary myocardial stress. Homocysteine elevation reflects nutritional deficiency (B12, folate, B6), renal insufficiency, or genetic hyperhomocysteinaemia (MTHFR C677T, CBS mutation) — and while associated with cardiovascular risk in observational data, B-vitamin supplementation has not uniformly reduced MACE in RCTs (VISP, NORVIT), necessitating careful clinical interpretation. Heart Shield Elite's integrated physician report interprets each analyte within the full clinical context — genetic predisposition, arterial stiffness, structural ECG changes, and composite risk scores — ensuring that intervention recommendations are calibrated, evidence-based, and aligned with ACC\/AHA 2023 and Singapore MOH Clinical Practice Guidelines.\u003c\/p\u003e\n\u003c\/div\u003e\n\n\u003cdiv style=\"margin-bottom:28px;padding:16px 20px;background:#fafcff;border:1px solid #d0e4f7;border-radius:6px;\"\u003e\n\u003cp style=\"font-weight:700;color:#0057a8;margin-bottom:8px;\"\u003eQ5: What specific interventions does the personalised cardiac protection protocol recommend for different risk tiers?\u003c\/p\u003e\n\u003cp style=\"margin:0;line-height:1.7;\"\u003eThe personalised cardiac protection protocol generated by Heart Shield Elite stratifies individuals into three actionable risk tiers based on composite biomarker, imaging, genetic, and ECG findings. \u003cstrong\u003eTier A (low-intermediate composite risk, Heart Health Age ≤5 years above chronological age, 10-year ASCVD \u0026lt;7.5%):\u003c\/strong\u003e Lifestyle optimisation protocol — dietary intervention targeting Mediterranean-pattern adherence (PREDIMED-Plus evidence base), structured aerobic exercise (≥150 min\/week moderate-intensity, ACC\/AHA Class I), sleep hygiene optimisation, and 12-month reassessment schedule. \u003cstrong\u003eTier B (intermediate-high risk, Heart Health Age 5–15 years above chronological, 10-year ASCVD 7.5–20%, or presence of CIMT plaque\/elevated Lp(a)\/high CAD-PRS quintile):\u003c\/strong\u003e Statin initiation discussion (rosuvastatin\/atorvastatin, ACC\/AHA Class IIa–I), structured cardiologist or preventive medicine physician referral, cardiac rehabilitation-grade exercise programme, and reassessment at 6 months. \u003cstrong\u003eTier C (high-very high risk, 10-year ASCVD \u0026gt;20%, Heart Health Age \u0026gt;15 years above chronological, abnormal ECG\/NT-proBNP\/hs-cTnI, or cf-PWV \u0026gt;12 m\/s):\u003c\/strong\u003e Urgent specialist cardiology referral, intensive LDL-C reduction targeting ApoB \u0026lt;0.7 g\/L (ESC\/EAS Class I, very-high-risk), consideration of ezetimibe or PCSK9 inhibitor add-on, antihypertensive optimisation, and reassessment at 3 months.\u003c\/p\u003e\n\u003c\/div\u003e\n\n\u003cscript type=\"application\/ld+json\"\u003e\n{\n  \"@context\": \"https:\/\/schema.org\/\",\n  \"@type\": \"Product\",\n  \"name\": \"Heart Shield Elite — Advanced 360° Cardiovascular Risk Assessment\",\n  \"description\": \"EMIS+ Heart Shield Elite: comprehensive cardiovascular risk assessment integrating hsCRP, NT-proBNP, hs-cTnI, homocysteine, fibrinogen, D-dimer, Lp(a), ApoB, ApoA-1, oxidised LDL, CAD polygenic risk score, carotid-femoral PWV, CIMT ultrasound, resting 12-lead ECG, Heart Health Age, 10-year ASCVD (PCE\/SCORE2), lifetime ASCVD risk, and personalised cardiac protection protocol. ISO 15189:2022 accredited. Singapore.\",\n  \"sku\": \"EMIS-HSE-899\",\n  \"brand\": {\n    \"@type\": \"Brand\",\n    \"name\": \"EMIS+\"\n  },\n  \"offers\": {\n    \"@type\": \"Offer\",\n    \"priceCurrency\": \"SGD\",\n    \"price\": \"899.00\",\n    \"availability\": \"https:\/\/schema.org\/InStock\",\n    \"url\": \"https:\/\/www.emis.asia\/products\/heart-shield-elite\"\n  },\n  \"additionalProperty\": [\n    {\"@type\": \"PropertyValue\", \"name\": \"Inflammatory Markers\", \"value\": \"hsCRP, fibrinogen, homocysteine, IL-6 — IFCC-standardised\"},\n    {\"@type\": \"PropertyValue\", \"name\": \"Cardiac Biomarkers\", \"value\": \"NT-proBNP, hs-cTnI, D-dimer — Roche Elecsys platform\"},\n    {\"@type\": \"PropertyValue\", \"name\": \"Advanced Lipid Panel\", \"value\": \"Lp(a) nmol\/L, ApoB g\/L, ApoA-1, oxidised LDL, ApoB\/ApoA-1 ratio\"},\n    {\"@type\": \"PropertyValue\", \"name\": \"Genetic CAD-PRS\", \"value\": \"Coronary Artery Disease Polygenic Risk Score ≥6.6M SNPs\"},\n    {\"@type\": \"PropertyValue\", \"name\": \"Arterial Stiffness\", \"value\": \"Carotid-femoral PWV m\/s; Augmentation Index AIx@75\"},\n    {\"@type\": \"PropertyValue\", \"name\": \"CIMT Ultrasound\", \"value\": \"Bilateral common carotid IMT mm; plaque characterisation; ASE\/EACVI protocol\"},\n    {\"@type\": \"PropertyValue\", \"name\": \"Electrocardiography\", \"value\": \"Resting 12-lead ECG; LVH criteria; QTc ms; rhythm analysis\"},\n    {\"@type\": \"PropertyValue\", \"name\": \"Risk Scores\", \"value\": \"10-year ASCVD PCE + SCORE2; Lifetime ASCVD; Heart Health Age\"},\n    {\"@type\": \"PropertyValue\", \"name\": \"Laboratory Accreditation\", \"value\": \"ISO 15189:2022; CAP-accredited partner laboratories\"},\n    {\"@type\": \"PropertyValue\", \"name\": \"Regulatory Compliance\", \"value\": \"Singapore HSA; ACC\/AHA 2023; ESC\/EAS 2021; Singapore MOH CPG\"}\n  ]\n}\n\u003c\/script\u003e\n\n\u003cdiv style=\"margin-top:28px;padding:14px 18px;background:#f5f5f5;border-radius:6px;font-size:13px;color:#444;line-height:1.65;\"\u003e\n\u003cstrong\u003eRegulatory and Methodological Framework:\u003c\/strong\u003e Heart Shield Elite is conducted within an ISO 15189:2022-accredited medical laboratory network with CAP (College of American Pathologists) external quality assurance programmes including EQAS, RIQAS, and Bio-Rad Liquichek. All biochemical assays comply with IFCC (International Federation of Clinical Chemistry and Laboratory Medicine) reference measurement procedures and WHO\/IFCC International Reference Preparations where applicable. Genetic CAD polygenic risk scoring methodology follows the Khera et al. 2018 Nature Genetics landmark study (PRSice-2 \/ LDpred2 algorithms) and the American Heart Association 2023 Precision Medicine in Cardiovascular Disease Advisory. Advanced lipid reporting (Lp(a) in nmol\/L) complies with the 2022 European Atherosclerosis Society (EAS) Lipoprotein(a) Consensus Statement. Arterial stiffness measurement follows ESH\/ESC 2023 hypertension guidelines pathological thresholds. CIMT protocol adheres to ASE\/EACVI 2008 consensus standards. 10-year cardiovascular risk is computed via the 2013\/2023 ACC\/AHA Pooled Cohort Equations (PCE) and the European SCORE2 algorithm (SCORE2 Working Group, European Heart Journal 2021). Lifetime ASCVD risk uses the Framingham Heart Study Lifetime Risk model. All clinical interpretation and cardiac protection protocol recommendations are aligned with ACC\/AHA 2023 Cardiovascular Prevention Guidelines, ESC\/EAS 2021 Dyslipidaemia Management Guidelines, and Singapore Ministry of Health Clinical Practice Guidelines on Cardiovascular Prevention. This assessment is conducted under the supervision of MOH-registered physicians in Singapore. Results are not intended to replace clinical consultation; participants with abnormal findings are advised to seek specialist cardiology review. Heart Shield Elite is indicated for adults aged 30–75 years with no prior MACE who are seeking proactive cardiovascular risk quantification and evidence-based prevention.\n\u003c\/div\u003e\n\n\u003cscript type=\"application\/ld+json\"\u003e\n{\n  \"@context\": \"https:\/\/schema.org\",\n  \"@type\": \"FAQPage\",\n  \"mainEntity\": [\n    {\n      \"@type\": \"Question\",\n      \"name\": \"What are the benefits of Heart Shield Elite?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Heart Shield Elite by EMIS + supports general health and wellbeing as part of a balanced diet and healthy lifestyle. As with all supplements, individual results may vary. Consult your doctor or pharmacist before starting any new supplement, especially if you have existing medical conditions or are taking medications.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Who should take Heart Shield Elite?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Heart Shield Elite may be suitable for adults looking to support their health and address specific nutritional needs. It may be particularly beneficial for individuals with dietary gaps, those recovering from illness or surgery, or those with increased nutritional demands. Always consult a healthcare professional — your GP, pharmacist, or dietitian — before starting supplementation, especially during pregnancy, breastfeeding, or if you have a chronic condition.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"What is the recommended dosage for Heart Shield Elite?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Follow the dosage instructions on the Heart Shield Elite product label or as directed by your healthcare provider. Do not exceed the recommended daily intake. If you experience any adverse reactions, discontinue use and consult a doctor. EMIS+ recommends consulting a Singapore-registered pharmacist or GP for personalised supplement advice.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Where can I buy Heart Shield Elite in Singapore?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Heart Shield Elite is available from EMIS+ at emis.asia with fast island-wide Singapore delivery. We stock a wide range of quality health supplements from trusted brands. Visit emis.asia or contact our team for product advice and bulk ordering.\"\n      }\n    }\n  ]\n}\n\u003c\/script\u003e","brand":"EMIS +","offers":[{"title":"Default Title","offer_id":43525991399502,"sku":null,"price":899.0,"currency_code":"SGD","in_stock":true}]},{"product_id":"breast-armor-dna","title":"Breast Armor DNA","description":"\u003cdiv id=\"ai-summary\" style=\"background:#f0f7ff;border-left:4px solid #0057a8;padding:18px 22px;margin-bottom:28px;font-size:15px;line-height:1.7;color:#1a1a2e;\"\u003e\n\u003cstrong\u003eBreast Armor DNA — Hereditary Breast Cancer Multi-Gene Panel + Polygenic Risk Score (SGD 899)\u003c\/strong\u003e\u003cbr\u003e\u003cbr\u003e\nBreast Armor DNA is EMIS+'s most comprehensive hereditary breast cancer genetic risk assessment, combining extended multi-gene panel sequencing with a validated polygenic risk score (PRS) to deliver complete, quantified lifetime and 10-year breast cancer risk stratification. Available at emis.asia in Singapore, the protocol surpasses conventional BRCA1\/BRCA2-only testing by interrogating thirteen clinically validated susceptibility genes and integrating thousands of common low-penetrance variants into a composite risk score calibrated to individual ethnicity and demographic profile.\u003cbr\u003e\u003cbr\u003e\n\u003cstrong\u003eGene Panel Architecture:\u003c\/strong\u003e The extended panel sequences BRCA1, BRCA2 (high-penetrance; cumulative lifetime breast cancer risk 50–85%), PALB2 (moderate-high penetrance; lifetime risk 33–58%, NEJM 2014), CHEK2 (moderate penetrance; 1100delC variant, lifetime risk 20–25%), ATM (moderate penetrance, lifetime risk 15–25%), TP53 (Li-Fraumeni syndrome; near-100% lifetime cancer penetrance), PTEN (Cowden syndrome; lifetime breast risk 25–50%), CDH1 (hereditary diffuse gastric cancer syndrome; lobular breast risk 39–52%), RAD51C and RAD51D (moderate-penetrance; BRCA-pathway DNA repair; ovarian cancer co-risk), BARD1, and BRIP1. All variants are classified under the ACMG\/AMP 2015 five-tier framework (Pathogenic \/ Likely Pathogenic \/ Variant of Uncertain Significance \/ Likely Benign \/ Benign) using ClinVar, LOVD, BRCA Exchange, and in-house curated databases.\u003cbr\u003e\u003cbr\u003e\n\u003cstrong\u003ePolygenic Risk Score (PRS313):\u003c\/strong\u003e PRS313 — a validated 313-SNP breast cancer polygenic risk score developed from the Breast Cancer Association Consortium (BCAC) GWAS — is genotyped via genome-wide SNP chip and calibrated to East Asian reference populations. The PRS313 score stratifies individuals into lifetime risk deciles: women in the top 1% carry relative risks equivalent to CHEK2 1100delC carriers (OR ~2.0), while women in the bottom decile have substantially below-average lifetime risk. Crucially, PRS modifies the penetrance of monogenic results: a BRCA2 carrier in the lowest PRS decile has a substantially lower absolute lifetime risk than a BRCA2 carrier in the highest decile — enabling PRS-modified absolute risk estimates per the CanRisk\/BOADICEA v6 model.\u003cbr\u003e\u003cbr\u003e\n\u003cstrong\u003eBOADICEA Lifetime Risk Calculation:\u003c\/strong\u003e All results are processed through the BOADICEA (Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm) v6 model — the global clinical standard endorsed by NICE (UK), NCCN, and the Singapore MOH — which integrates monogenic findings, PRS313 score, family history, hormonal\/reproductive factors, mammographic density (where available), and lifestyle parameters to compute individualised 10-year and lifetime absolute breast and ovarian cancer risk percentages. BOADICEA v6 is the only model validated for combined monogenic + PRS + epidemiological factor integration in Asian and mixed-ethnicity populations.\u003cbr\u003e\u003cbr\u003e\n\u003cstrong\u003eVariant Reporting and Clinical Interpretation:\u003c\/strong\u003e All sequencing is performed by next-generation sequencing (NGS) using the Illumina NovaSeq platform with mean depth ≥500× for exon regions and ≥50× for intronic splice regions. Large genomic rearrangements (LGR) — including BRCA1 exon 13 duplication and exon 1-7 deletion — are detected by multiplex ligation-dependent probe amplification (MLPA). Variant interpretation follows ACMG\/AMP 2015 guidelines with gene-specific adaptations from ClinGen BRCA1\/2 Expert Panel specifications. A board-certified clinical geneticist reviews all Pathogenic and Likely Pathogenic findings. Variants of Uncertain Significance (VUS) are reported with VUS management guidance per current NCCN recommendations.\u003cbr\u003e\u003cbr\u003e\n\u003cstrong\u003eCascade Testing and Surveillance Protocols:\u003c\/strong\u003e Breast Armor DNA includes carrier cascade testing guidance, identifying which first-degree and second-degree relatives should undergo targeted variant testing. Risk-stratified surveillance recommendations are calibrated to the BOADICEA lifetime risk output: individuals with lifetime risk ≥30% receive annual breast MRI + mammography protocols per NICE CG164 and NCCN Genetic\/Familial High-Risk guidelines; those with lifetime risk 20–29% receive mammography with supplemental ultrasound; those with lifetime risk \u0026lt;20% receive standard population-based screening. For TP53 carriers, Li-Fraumeni syndrome whole-body MRI (annual, from age 20) is recommended per Villani et al. (Lancet Oncology 2016).\n\u003c\/div\u003e\n\n\u003ch2 style=\"color:#0057a8;font-size:20px;margin-top:32px;\"\u003eBreast Armor DNA — Gene Panel and Methodology Specifications\u003c\/h2\u003e\n\u003ctable style=\"width:100%;border-collapse:collapse;font-size:14px;margin-bottom:28px;\"\u003e\n\u003cthead\u003e\n\u003ctr style=\"background:#0057a8;color:#fff;\"\u003e\n\u003cth style=\"padding:10px 14px;text-align:left;width:20%;\"\u003eGene\u003c\/th\u003e\n\u003cth style=\"padding:10px 14px;text-align:left;width:18%;\"\u003ePenetrance \/ Risk Category\u003c\/th\u003e\n\u003cth style=\"padding:10px 14px;text-align:left;width:28%;\"\u003eLifetime Breast Cancer Risk (approximate)\u003c\/th\u003e\n\u003cth style=\"padding:10px 14px;text-align:left;width:34%;\"\u003eAssociated Syndrome \/ Additional Cancer Risk\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr style=\"background:#f9f9f9;\"\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003eBRCA1\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eHigh penetrance\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e57–72% (by age 80, Chen \u0026amp; Parmigiani 2007)\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eHereditary Breast and Ovarian Cancer (HBOC); ovarian cancer 44%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003eBRCA2\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eHigh penetrance\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e45–69% (by age 80)\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eHBOC; ovarian cancer 17%; male breast cancer; pancreatic cancer\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#f9f9f9;\"\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003ePALB2\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eModerate-high penetrance\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e33–58% (NEJM 2014, Antoniou et al.)\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eBRCA-pathway interactor; pancreatic cancer co-risk\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003eCHEK2\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eModerate penetrance\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e20–25% (1100delC variant); 15–20% (other PV)\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eCell-cycle checkpoint kinase; colorectal and prostate co-risk\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#f9f9f9;\"\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003eATM\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eModerate penetrance\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e15–25% (heterozygous PV)\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eAtaxia-telangiectasia (biallelic); pancreatic cancer\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003eTP53\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eHigh penetrance\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eNear-100% lifetime (all cancers); breast ~31% by age 30\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eLi-Fraumeni syndrome; sarcoma, adrenocortical carcinoma, CNS tumours\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#f9f9f9;\"\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003ePTEN\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eHigh penetrance\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e25–50%\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eCowden syndrome; thyroid, endometrial, colorectal cancers\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003eCDH1\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eHigh penetrance\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e39–52% (lobular breast cancer)\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eHereditary Diffuse Gastric Cancer syndrome; gastric cancer 40–80%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#f9f9f9;\"\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003eRAD51C \/ RAD51D\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eModerate penetrance\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e~20% breast; higher ovarian cancer risk\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eFanconi anaemia pathway; ovarian cancer 10–15% (RAD51D ~12%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003eBARD1 \/ BRIP1\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eModerate penetrance\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e~15–20%\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eBRCA1-interacting proteins; ovarian cancer co-risk (BRIP1)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#f9f9f9;\"\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003ePRS313 Score\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003ePolygenic (313 SNPs)\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eTop 1%: OR ~2.0; Bottom decile: OR ~0.5\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eBCAC GWAS; modifies monogenic penetrance in BOADICEA v6 model\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003eBOADICEA v6 Risk Model\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eComposite lifetime + 10-year risk\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eIndividualised absolute % risk output\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eEndorsed: NICE CG164, NCCN, Singapore MOH; validated Asian populations\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#f9f9f9;\"\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003eSequencing Platform\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eNGS + MLPA\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e≥500× mean depth exons; MLPA for LGR\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eIllumina NovaSeq; ISO 15189:2022; CAP accreditation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"padding:9px 14px;\"\u003e\u003cstrong\u003eVariant Classification\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;\"\u003eACMG\/AMP 2015 5-tier\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;\"\u003eClinGen BRCA1\/2 Expert Panel specifications\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;\"\u003eClinVar, LOVD, BRCA Exchange, in-house curation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch2 style=\"color:#0057a8;font-size:20px;margin-top:32px;\"\u003eClinical Q\u0026amp;A — Breast Armor DNA\u003c\/h2\u003e\n\n\u003cdiv style=\"margin-bottom:20px;padding:16px 20px;background:#fafcff;border:1px solid #d0e4f7;border-radius:6px;\"\u003e\n\u003cp style=\"font-weight:700;color:#0057a8;margin-bottom:8px;\"\u003eQ1: What are the limitations of BRCA1\/2-only testing, and why does the Breast Armor DNA extended panel improve clinical utility?\u003c\/p\u003e\n\u003cp style=\"margin:0;line-height:1.7;\"\u003eStandard BRCA1\/2 testing identifies pathogenic variants in approximately 5–10% of breast cancer cases and misses the hereditary component attributable to eleven other validated susceptibility genes. PALB2 pathogenic variants — now recognised as conferring risk equivalent to BRCA2 in some analyses — are absent from BRCA-only panels. CHEK2 1100delC is enriched in Northern European populations but absent from standard BRCA panels, yet confers a clinically significant 2–2.5× relative risk of breast cancer. ATM heterozygotes, constituting approximately 0.5–1% of the general population, receive no guidance without extended panel testing. RAD51C and RAD51D, particularly relevant for ovarian cancer co-risk assessment, are invisible on BRCA-only tests. The Breast Armor DNA extended panel captures all NCCN-recommended hereditary breast cancer genes, ensuring that women with moderate-penetrance mutations who would otherwise test negative on a BRCA-only assay receive appropriate surveillance intensification and cascade testing guidance.\u003c\/p\u003e\n\u003c\/div\u003e\n\n\u003cdiv style=\"margin-bottom:20px;padding:16px 20px;background:#fafcff;border:1px solid #d0e4f7;border-radius:6px;\"\u003e\n\u003cp style=\"font-weight:700;color:#0057a8;margin-bottom:8px;\"\u003eQ2: How does the PRS313 polygenic risk score modify the clinical interpretation of a monogenic finding — for example, a BRCA2 pathogenic variant?\u003c\/p\u003e\n\u003cp style=\"margin:0;line-height:1.7;\"\u003eThe interaction between monogenic high-penetrance mutations and the polygenic background is substantial and clinically actionable. A BRCA2 pathogenic variant carrier in the lowest PRS313 decile has an estimated lifetime breast cancer risk of approximately 40–45%, whereas the same carrier in the highest PRS313 decile faces a lifetime risk of 60–70% — a difference that materially alters the timing and intensity of risk-reducing interventions. The BOADICEA v6 model, which integrates both dimensions, enables PRS-modified absolute risk estimates that personalise surveillance schedules: a BRCA2 carrier with high PRS may begin annual MRI at age 25 rather than 30; a CHEK2 1100delC carrier with low PRS may defer to enhanced mammography rather than MRI. Conversely, women without identifiable monogenic mutations but in the top 5% of PRS313 distribution carry lifetime risks of 20–25% — qualifying for supplemental surveillance per ACC\/AHA and NICE thresholds — information that is entirely missed without PRS integration.\u003c\/p\u003e\n\u003c\/div\u003e\n\n\u003cdiv style=\"margin-bottom:20px;padding:16px 20px;background:#fafcff;border:1px solid #d0e4f7;border-radius:6px;\"\u003e\n\u003cp style=\"font-weight:700;color:#0057a8;margin-bottom:8px;\"\u003eQ3: What is the clinical management protocol for a woman who receives a Variant of Uncertain Significance (VUS) in BRCA1 or PALB2?\u003c\/p\u003e\n\u003cp style=\"margin:0;line-height:1.7;\"\u003eA Variant of Uncertain Significance (VUS) indicates a genetic change for which current evidence is insufficient to classify definitively as disease-causing or benign — it does not equal a positive result for clinical management purposes. Per ACMG\/AMP 2015 guidelines, ClinGen BRCA1\/2 Expert Panel specifications, and NCCN Genetic\/Familial High-Risk Breast Cancer guidelines (Category 1 recommendation), VUS results should not alter clinical management beyond what the individual's personal and family history would dictate without genetic testing. Breast Armor DNA provides a VUS management guidance document explaining: (1) the probability of the VUS reclassifying to Pathogenic (approximately 5–10% of VUS reclassify over 5–10 year follow-up; Harrison et al., Genetics in Medicine 2021); (2) the mechanism for reclassification notification — EMIS+ maintains a VUS registry and notifies affected individuals when reclassification occurs; (3) interim surveillance based on family history alone using BOADICEA v6 family history-only risk estimates. Cascade testing of relatives for VUS is generally discouraged unless family history context provides additional segregation evidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\n\u003cdiv style=\"margin-bottom:20px;padding:16px 20px;background:#fafcff;border:1px solid #d0e4f7;border-radius:6px;\"\u003e\n\u003cp style=\"font-weight:700;color:#0057a8;margin-bottom:8px;\"\u003eQ4: What are the surveillance recommendations stratified by BOADICEA lifetime risk output?\u003c\/p\u003e\n\u003cp style=\"margin:0;line-height:1.7;\"\u003eBreast Armor DNA translates BOADICEA v6 absolute lifetime risk into one of four evidence-based surveillance tiers. \u003cstrong\u003ePopulation risk (lifetime risk \u0026lt;17%):\u003c\/strong\u003e Standard Singapore national breast screening programme — biennial mammography from age 40–49, annual from 50–69 (Singapore Cancer Registry \/ MOH guidelines). \u003cstrong\u003eModerate risk (lifetime risk 17–29%):\u003c\/strong\u003e Enhanced annual mammography with supplemental breast ultrasound; clinical breast examination annually; consider MRI if mammographic density BI-RADS D (heterogeneously or extremely dense) per ACOG Practice Bulletin 2022. \u003cstrong\u003eHigh risk (lifetime risk ≥30% or BRCA1\/2 \/ PALB2 \/ TP53 \/ PTEN pathogenic variant):\u003c\/strong\u003e Annual breast MRI (contrast-enhanced, optimally Days 7–14 of menstrual cycle) + annual mammography + clinical breast examination 6-monthly; risk-reducing options discussion (chemoprevention with tamoxifen\/raloxifene\/exemestane per IBIS-I\/II evidence; risk-reducing salpingo-oophorectomy for BRCA1 carriers by age 35–40; risk-reducing mastectomy discussion per individual preference and risk magnitude). \u003cstrong\u003eTP53 carriers (Li-Fraumeni):\u003c\/strong\u003e Whole-body MRI annually from age 20; brain MRI annually; colonoscopy every 2–5 years; dermatology annually — per Villani et al. Lancet Oncology 2016 LFS surveillance protocol.\u003c\/p\u003e\n\u003c\/div\u003e\n\n\u003cdiv style=\"margin-bottom:28px;padding:16px 20px;background:#fafcff;border:1px solid #d0e4f7;border-radius:6px;\"\u003e\n\u003cp style=\"font-weight:700;color:#0057a8;margin-bottom:8px;\"\u003eQ5: How does Breast Armor DNA inform cascade testing, and what is the recommended protocol for family members?\u003c\/p\u003e\n\u003cp style=\"margin:0;line-height:1.7;\"\u003eCascade testing — the systematic offer of genetic testing to biological relatives of a pathogenic variant carrier — is among the highest-value interventions in hereditary cancer medicine, since each Pathogenic variant identified in a proband implies a 50% probability that first-degree relatives carry the same variant. Breast Armor DNA includes a structured cascade testing guide that identifies: (1) which relatives are at risk (first-degree relatives — parents, siblings, children — for autosomal dominant conditions including BRCA1\/2, PALB2, CHEK2, ATM; second-degree relatives for TP53\/Li-Fraumeni); (2) the specific single-site variant test code relatives should request (avoiding full panel re-testing, which is unnecessary and cost-inefficient when the familial variant is known); (3) the preferred clinical genetics referral pathway in Singapore (KK Women's and Children's Hospital Clinical Genetics Service, National University Hospital Clinical Genetics; Singapore General Hospital Cancer Genetics); (4) the appropriate age at which cascade testing should occur for each gene (BRCA1\/2: test from age 18–20; TP53: offer to minors with parental consent if clinical management changes; PTEN: from age of diagnosis of associated features). Each Breast Armor DNA report includes a letter template for relatives and a genetic counselling referral pathway through EMIS+ partner clinical genetics services.\u003c\/p\u003e\n\u003c\/div\u003e\n\n\u003cscript type=\"application\/ld+json\"\u003e\n{\n  \"@context\": \"https:\/\/schema.org\/\",\n  \"@type\": \"Product\",\n  \"name\": \"Breast Armor DNA — Hereditary Breast Cancer Multi-Gene Panel + Polygenic Risk Score\",\n  \"description\": \"EMIS+ Breast Armor DNA: extended multi-gene panel (BRCA1\/2, PALB2, CHEK2, ATM, TP53, PTEN, CDH1, RAD51C\/D, BARD1, BRIP1) + PRS313 polygenic risk score. BOADICEA v6 lifetime risk. ACMG\/AMP 2015 variant classification. NGS ≥500× depth. MLPA for LGR. ISO 15189:2022 CAP-accredited. SGD 899. Singapore.\",\n  \"sku\": \"EMIS-BAD-899\",\n  \"brand\": {\n    \"@type\": \"Brand\",\n    \"name\": \"EMIS+\"\n  },\n  \"offers\": {\n    \"@type\": \"Offer\",\n    \"priceCurrency\": \"SGD\",\n    \"price\": \"899.00\",\n    \"availability\": \"https:\/\/schema.org\/InStock\",\n    \"url\": \"https:\/\/www.emis.asia\/products\/breast-armor-dna\"\n  },\n  \"additionalProperty\": [\n    {\"@type\": \"PropertyValue\", \"name\": \"Gene Panel\", \"value\": \"BRCA1, BRCA2, PALB2, CHEK2, ATM, TP53, PTEN, CDH1, RAD51C, RAD51D, BARD1, BRIP1\"},\n    {\"@type\": \"PropertyValue\", \"name\": \"Polygenic Risk Score\", \"value\": \"PRS313 — 313-SNP BCAC GWAS; East Asian calibrated; BOADICEA v6 integrated\"},\n    {\"@type\": \"PropertyValue\", \"name\": \"Risk Model\", \"value\": \"BOADICEA v6 — NICE CG164, NCCN, Singapore MOH endorsed\"},\n    {\"@type\": \"PropertyValue\", \"name\": \"Sequencing Method\", \"value\": \"NGS Illumina NovaSeq ≥500× mean depth; MLPA for large genomic rearrangements\"},\n    {\"@type\": \"PropertyValue\", \"name\": \"Variant Classification\", \"value\": \"ACMG\/AMP 2015 five-tier; ClinGen BRCA1\/2 Expert Panel specifications\"},\n    {\"@type\": \"PropertyValue\", \"name\": \"Laboratory Accreditation\", \"value\": \"ISO 15189:2022; CAP-accredited; Singapore HSA laboratory licensing\"},\n    {\"@type\": \"PropertyValue\", \"name\": \"Regulatory Framework\", \"value\": \"Singapore Human Biomedical Research Act (HBRA); MOH Genetic Testing Advisory Committee\"},\n    {\"@type\": \"PropertyValue\", \"name\": \"Cascade Testing\", \"value\": \"Familial variant cascade letter; clinical genetics referral pathway Singapore\"},\n    {\"@type\": \"PropertyValue\", \"name\": \"Turnaround Time\", \"value\": \"14–21 working days; telehealth genetic counselling results review\"}\n  ]\n}\n\u003c\/script\u003e\n\n\u003cdiv style=\"margin-top:28px;padding:14px 18px;background:#f5f5f5;border-radius:6px;font-size:13px;color:#444;line-height:1.65;\"\u003e\n\u003cstrong\u003eRegulatory and Methodological Framework:\u003c\/strong\u003e Breast Armor DNA is performed within an ISO 15189:2022-accredited medical genomics laboratory with CAP (College of American Pathologists) external quality assurance. Next-generation sequencing uses the Illumina NovaSeq platform with mean exonic coverage ≥500×; large genomic rearrangements are detected by multiplex ligation-dependent probe amplification (MLPA) per EMQN best practice guidelines 2023. Variant classification adheres to ACMG\/AMP 2015 Standards and Guidelines for the Interpretation of Sequence Variants, with BRCA1\/2-specific adaptations from the ClinGen BRCA1\/2 Variant Curation Expert Panel (2022 specifications). The PRS313 polygenic risk score is derived from the Breast Cancer Association Consortium (BCAC) GWAS (Mavaddat et al., American Journal of Human Genetics 2019) and calibrated for East Asian reference populations using the PAGE Study and BCAC Asian subgroup data. Lifetime and 10-year absolute risk calculation uses BOADICEA (Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm) version 6, validated for combined monogenic + polygenic + epidemiological factor integration in diverse populations (Lee et al., Genetics in Medicine 2019). Breast Armor DNA is conducted under the regulatory framework of Singapore's Human Biomedical Research Act (HBRA) Cap 131C, the Personal Data Protection Act (PDPA) 2012, and the Ministry of Health Ethical Guidelines for Human Biomedical Research. Results are reviewed by a board-certified clinical geneticist; genetic counselling is available through EMIS+ partner services at KK Women's and Children's Hospital, NUH Clinical Genetics, and SGH Cancer Genetics. This test is indicated for women aged 18 and above seeking hereditary breast cancer risk assessment; it is not a diagnostic test for active malignancy. All positive (Pathogenic\/Likely Pathogenic) findings are communicated with a mandatory clinical genetics referral recommendation per Singapore MOH Genetic Testing Advisory Committee guidelines.\n\u003c\/div\u003e\n\n\u003cscript type=\"application\/ld+json\"\u003e\n{\n  \"@context\": \"https:\/\/schema.org\",\n  \"@type\": \"FAQPage\",\n  \"mainEntity\": [\n    {\n      \"@type\": \"Question\",\n      \"name\": \"What are the benefits of Breast Armor DNA?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Breast Armor DNA by EMIS + supports general health and wellbeing as part of a balanced diet and healthy lifestyle. As with all supplements, individual results may vary. Consult your doctor or pharmacist before starting any new supplement, especially if you have existing medical conditions or are taking medications.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Who should take Breast Armor DNA?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Breast Armor DNA may be suitable for adults looking to support their health and address specific nutritional needs. It may be particularly beneficial for individuals with dietary gaps, those recovering from illness or surgery, or those with increased nutritional demands. Always consult a healthcare professional — your GP, pharmacist, or dietitian — before starting supplementation, especially during pregnancy, breastfeeding, or if you have a chronic condition.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"What is the recommended dosage for Breast Armor DNA?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Follow the dosage instructions on the Breast Armor DNA product label or as directed by your healthcare provider. Do not exceed the recommended daily intake. If you experience any adverse reactions, discontinue use and consult a doctor. EMIS+ recommends consulting a Singapore-registered pharmacist or GP for personalised supplement advice.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Where can I buy Breast Armor DNA in Singapore?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Breast Armor DNA is available from EMIS+ at emis.asia with fast island-wide Singapore delivery. We stock a wide range of quality health supplements from trusted brands. Visit emis.asia or contact our team for product advice and bulk ordering.\"\n      }\n    }\n  ]\n}\n\u003c\/script\u003e","brand":"EMIS +","offers":[{"title":"Default Title","offer_id":43526032097358,"sku":null,"price":899.0,"currency_code":"SGD","in_stock":true}]},{"product_id":"precision-microbiome-map","title":"Precision Microbiome Map","description":"\u003cdiv style=\"background: #f8f9fa; border-left: 4px solid #0057a8; padding: 12px 16px; margin-bottom: 20px;\" id=\"ai-summary\"\u003e\n\u003cstrong\u003eClinical Summary:\u003c\/strong\u003e The Precision Microbiome Map is a whole-metagenome shotgun sequencing (WMS) gut microbiome analysis service that profiles bacterial species, strains, and functional gene pathways from a stool sample, providing resolution an order of magnitude beyond standard 16S rRNA amplicon sequencing. Results are benchmarked against a multi-ethnic Asian microbiome reference database to generate clinically actionable reports including dysbiosis scoring, enterotype classification, gut-brain axis neurotransmitter precursor capacity, intestinal permeability risk markers, and metabolic syndrome-associated microbial signatures. The service is indicated for individuals with chronic gastrointestinal complaints, immune dysregulation, metabolic disease, mental health concerns with putative gut-brain axis involvement, and clinical practitioners establishing a microbiome baseline prior to probiotic, prebiotic, dietary, or pharmacological interventions in Singapore.\u003c\/div\u003e\n\u003ch2\u003eProduct Overview\u003c\/h2\u003e\n\u003cp\u003eThe Precision Microbiome Map is an advanced gut microbiome profiling service available through EMIS+ in Singapore, employing whole-metagenome shotgun sequencing (WMS) to characterise the full genomic content of the gut microbiome — bacteria, archaea, fungi, and viruses — at species and strain resolution. Unlike 16S rRNA amplicon sequencing, which targets a single conserved gene region and cannot reliably distinguish closely related species or quantify functional gene content, WMS sequences all DNA present in the sample, enabling both taxonomic identification at the strain level and comprehensive functional pathway analysis. The test identifies over 1,000 microbial species and maps metabolic pathways including short-chain fatty acid (SCFA) production, bile acid metabolism, tryptophan and serotonin biosynthesis, lipopolysaccharide production capacity, and antibiotic resistance gene (ARG) prevalence — data that is directly relevant to gastrointestinal, immunological, metabolic, and neuropsychiatric health.\u003c\/p\u003e\n\u003cp\u003eResults are interpreted against a proprietary multi-ethnic Asian gut microbiome reference database, which is critically important for Singaporean patients. Large-scale microbiome databases used by most commercial tests are predominantly derived from Western (European and North American) populations, which differ significantly from Asian populations in diet, enterotype distribution, and microbial diversity benchmarks. Benchmarking against an Asian-representative reference population increases the specificity and clinical relevance of dysbiosis detection, reduces false-positive flagging of Asian-common bacteria as pathological, and enables more accurate personalisation of dietary and probiotic recommendations for individuals in Singapore's multi-ethnic population. The service includes a detailed clinical report, personalised dietary and supplement recommendations based on identified microbiome deficits, and a repeat test protocol designed for post-intervention monitoring.\u003c\/p\u003e\n\u003ch2\u003eSpecifications\u003c\/h2\u003e\n\u003ctable style=\"width: 100%; border-collapse: collapse; font-size: 14px;\" cellspacing=\"0\" cellpadding=\"8\" border=\"1\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eSequencing Technology\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eWhole-metagenome shotgun sequencing (WMS); Illumina NovaSeq platform\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eSequencing Depth\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eMinimum 10 million reads per sample; typical depth 15–20 million reads\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eResolution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSpecies and strain-level identification; \u0026gt;1,000 microbial species profiled\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003evs. 16S rRNA\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eWMS provides 10–100x greater taxonomic resolution and full functional gene pathway data; 16S cannot distinguish strain-level differences or quantify metabolic function\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eReference Database\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eMulti-ethnic Asian gut microbiome reference database; Southeast Asian population-representative cohort\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eSample Type\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eStool sample (self-collected); stabilisation buffer included for ambient temperature transport\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eTurnaround Time\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e4–6 weeks from sample receipt at laboratory\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eISO Compliance\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLaboratory operations compliant with ISO 15189:2022 for medical laboratory quality; sequencing facility holds ISO 9001:2015 certification\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eRegulatory Status (Singapore)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eConsumer microbiome wellness service; not classified as an IVD medical device under HSA Health Products (Medical Devices) Regulations 2010\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eReports Included\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eTaxonomic composition, diversity indices (Shannon, Simpson), dysbiosis score, enterotype, functional pathway map, personalised dietary and probiotic recommendations\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eFunctional Pathways Reported\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSCFA production, bile acid metabolism, tryptophan\/serotonin biosynthesis, intestinal permeability markers, antibiotic resistance genes (ARGs), inflammation-associated microbes\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ch2\u003eClinical Indications and Applications\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eChronic gastrointestinal disorders:\u003c\/strong\u003e Establishing a microbiome baseline for individuals with irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), functional dyspepsia, or unexplained bloating and altered bowel habits, enabling targeted probiotic and dietary intervention based on specific dysbiosis patterns identified at species resolution.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMetabolic syndrome and type 2 diabetes:\u003c\/strong\u003e Profiling metabolic syndrome-associated microbial signatures including reduced Akkermansia muciniphila, Faecalibacterium prausnitzii, and butyrate-producing Lachnospiraceae, alongside elevated Prevotella and LPS-producing Proteobacteria — patterns correlated with insulin resistance and glycaemic dysregulation in multiple Asian-population studies.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eImmune dysregulation and autoimmune conditions:\u003c\/strong\u003e Identifying microbiome patterns associated with intestinal permeability, low microbial diversity, and reduced regulatory T-cell–promoting bacteria (Clostridia clusters IV and XIV), relevant for practitioners managing IBD, psoriasis, rheumatoid arthritis, and atopic dermatitis in Singapore.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMental health and gut-brain axis assessment:\u003c\/strong\u003e Quantifying neurotransmitter precursor-producing microbes including serotonin producers (Enterochromaffin cells, Clostridiales), GABA producers (Lactobacillus and Bifidobacterium spp.), and tryptophan metabolisers, relevant for patients with depression, anxiety, or sleep disorders with suspected gut-brain axis involvement.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePre- and post-intervention microbiome monitoring:\u003c\/strong\u003e Providing baseline and follow-up data to quantify microbiome shifts in response to antibiotic therapy (and subsequent recovery), probiotic or prebiotic supplementation, dietary modification (e.g. Mediterranean diet adoption), or faecal microbiota transplantation (FMT) protocols.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePreventive health and longevity programmes:\u003c\/strong\u003e Integrating microbiome data into corporate health screening, longevity programme baselines, or annual preventive health panels for individuals seeking a multi-system biological assessment beyond conventional blood biomarkers.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eQ: What is the clinical advantage of whole-metagenome shotgun sequencing over 16S rRNA testing?\u003c\/strong\u003e\u003cbr\u003eA: The 16S rRNA gene is a single conserved genomic region used to classify bacteria at the genus level in most consumer gut tests. It cannot reliably distinguish species within a genus (e.g. cannot differentiate Lactobacillus rhamnosus from L. acidophilus), cannot detect fungi or viruses, and cannot assess metabolic gene content. WMS sequences all DNA in the sample, enabling strain-level bacterial identification, full eukaryotic and viral profiling, and comprehensive functional pathway analysis — including SCFA production capacity, ARG burden, and specific enzyme-level metabolic functions. For clinical decision-making involving targeted probiotic selection or antibiotic stewardship, WMS provides materially superior data.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eQ: Why is an Asian-specific microbiome reference database important for Singaporean patients?\u003c\/strong\u003e\u003cbr\u003eA: The gut microbiome composition differs substantially between populations due to differences in diet, genetics, and early-life microbial exposure. Most commercial tests (e.g. Thryve, Viome, Atlas) benchmark against predominantly Caucasian reference cohorts. Using these references to assess Singaporean patients can falsely flag Asian-common bacteria as dysbiotic, underestimate healthy diversity ranges for Asian enterotypes, and generate dietary recommendations calibrated to Western food patterns. The Precision Microbiome Map uses an Asian-representative reference database, significantly improving the specificity and clinical relevance of results for Chinese, Malay, and Indian Singaporean populations.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eQ: Can this test diagnose specific diseases such as colorectal cancer or IBD?\u003c\/strong\u003e\u003cbr\u003eA: The Precision Microbiome Map is a wellness and research-grade microbiome profiling service, not a diagnostic medical device as defined under the HSA Health Products (Medical Devices) Regulations 2010. It does not produce a clinical diagnosis. While certain microbial signatures are statistically associated with conditions including colorectal cancer (e.g. elevated Fusobacterium nucleatum), IBD (e.g. Faecalibacterium prausnitzii depletion), and type 2 diabetes, these associations are correlational. Patients with symptoms suggestive of gastrointestinal disease should seek evaluation from a Singapore-registered gastroenterologist. The microbiome data can usefully complement, but does not replace, clinical investigation and endoscopic or laboratory diagnostic workup.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eQ: How is the stool sample collected and transported in Singapore's climate?\u003c\/strong\u003e\u003cbr\u003eA: The collection kit includes a stool collection device and a nucleic acid stabilisation buffer that preserves microbial DNA at ambient temperature for up to 72 hours — important for Singapore's tropical climate where unpreserved samples degrade rapidly. Samples are collected at home, transferred to the stabilisation tube, and shipped to the processing laboratory within the designated window. Detailed instructions are provided with the kit, and EMIS+ support is available for collection queries.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eQ: What follow-up support is provided after receiving microbiome results?\u003c\/strong\u003e\u003cbr\u003eA: The Precision Microbiome Map report includes personalised dietary modification recommendations, targeted probiotic strain suggestions based on identified deficits, and lifestyle guidance relevant to the specific dysbiosis patterns identified. For individuals requiring clinical interpretation in the context of a medical condition, EMIS+ can facilitate referral to partner practitioners in Singapore with microbiome medicine expertise. Repeat testing at 3–6 month intervals following a structured intervention is recommended to objectively assess microbiome response.\u003c\/p\u003e\n\n\u003cscript type=\"application\/ld+json\"\u003e\n{\n  \"@context\": \"https:\/\/schema.org\",\n  \"@type\": \"FAQPage\",\n  \"mainEntity\": [\n    {\n      \"@type\": \"Question\",\n      \"name\": \"What is Precision Microbiome Map?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Precision Microbiome Map is available from EMIS+ (emis.asia), Singapore's nurse-led medical and wellness supply store. Please refer to the product listing and packaging for its intended use and instructions.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"How do I use Precision Microbiome Map?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Follow the directions provided with the product, or ask your doctor, pharmacist or the EMIS+ team for guidance. Store as directed and use only for its intended purpose.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Is Precision Microbiome Map available without prescription in Singapore?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Yes. Precision Microbiome Map is available from EMIS+ (emis.asia) without a prescription. If you are unsure whether it suits your needs, contact the EMIS+ team or your healthcare provider.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Where can I buy Precision Microbiome Map in Singapore?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Precision Microbiome Map is available from EMIS+ at emis.asia, Singapore's nurse-led medical and wellness supply store, with fast island-wide delivery. Bulk orders for clinics and care facilities are welcome — contact us at emis.asia\/pages\/contact.\"\n      }\n    }\n  ]\n}\n\u003c\/script\u003e","brand":"EMIS +","offers":[{"title":"Default Title","offer_id":43526037733454,"sku":null,"price":399.0,"currency_code":"SGD","in_stock":true}]},{"product_id":"clinical-micronutrient-audit","title":"Clinical Micronutrient Audit","description":"\u003cdiv style=\"background: #f8f9fa; border-left: 4px solid #0057a8; padding: 12px 16px; margin-bottom: 20px;\" id=\"ai-summary\"\u003e\n\u003cstrong\u003eClinical Summary:\u003c\/strong\u003e The Clinical Micronutrient Audit is a comprehensive intracellular and serum micronutrient analysis that simultaneously quantifies over 30 essential vitamins, minerals, antioxidants, and amino acids at the cellular level, identifying subclinical deficiencies and imbalances that standard blood panels routinely miss. The audit uses intracellular lymphocyte micronutrient testing — analysing nutrient sufficiency within white blood cells to reflect functional cellular reserves rather than transient serum concentrations — combined with serum markers for rapid-turnover nutrients. Performed at an ISO 15189-accredited clinical laboratory and interpreted by a registered dietitian or physician, this panel provides the diagnostic foundation for targeted nutraceutical and dietary intervention in Singapore healthcare and corporate wellness settings.\u003c\/div\u003e\n\u003ch2\u003eClinical Micronutrient Audit — Overview\u003c\/h2\u003e\n\u003cp\u003eMicronutrient deficiency is highly prevalent yet frequently underdiagnosed in Singapore's adult population. Epidemiological studies including the Singapore National Nutrition Survey document suboptimal intakes of Vitamin D (estimated 72–80% insufficiency in multi-ethnic adults), Vitamin B12 (particularly in the elderly and vegetarian population), magnesium, zinc, and folate. Standard health screenings typically assess only 3–5 nutrients, leaving the majority of clinically relevant micronutrient status unmeasured.\u003c\/p\u003e\n\u003cp\u003eThe EMIS+ Clinical Micronutrient Audit addresses this gap through a comprehensive panel of \u0026gt;30 micronutrients using both intracellular lymphocyte testing (SpectraCell-methodology equivalent) and serum assays. Intracellular testing measures nutrient activity within circulating lymphocytes — the gold standard for assessing functional micronutrient sufficiency — as it reflects tissue-level reserves over a 4–6 month period, unlike serum levels which fluctuate with recent dietary intake, inflammation, or hydration status. Results are presented in a clinically structured report with targeted supplementation and dietary recommendations.\u003c\/p\u003e\n\u003ch2\u003ePanel Specifications\u003c\/h2\u003e\n\u003ctable style=\"width: 100%; border-collapse: collapse; font-size: 14px;\"\u003e\n\u003cthead\u003e\n\u003ctr style=\"background: #0057a8; color: #fff;\"\u003e\n\u003cth style=\"padding: 8px; text-align: left; border: 1px solid #ddd;\"\u003eParameter\u003c\/th\u003e\n\u003cth style=\"padding: 8px; text-align: left; border: 1px solid #ddd;\"\u003eSpecification\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr style=\"background: #fff;\"\u003e\n\u003ctd style=\"padding: 8px; border: 1px solid #ddd;\"\u003e\u003cstrong\u003eTest Methodology\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding: 8px; border: 1px solid #ddd;\"\u003eIntracellular lymphocyte micronutrient analysis + serum \/ plasma assays\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background: #f9f9f9;\"\u003e\n\u003ctd style=\"padding: 8px; border: 1px solid #ddd;\"\u003e\u003cstrong\u003eNumber of Markers\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding: 8px; border: 1px solid #ddd;\"\u003e\u0026gt;30 micronutrients (vitamins, minerals, antioxidants, amino acids)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background: #fff;\"\u003e\n\u003ctd style=\"padding: 8px; border: 1px solid #ddd;\"\u003e\u003cstrong\u003eVitamins Assessed\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding: 8px; border: 1px solid #ddd;\"\u003eA, B1 (Thiamine), B2 (Riboflavin), B3 (Niacin), B5 (Pantothenate), B6, B7 (Biotin), B9 (Folate), B12, C, D (25-OH), E, K1, K2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background: #f9f9f9;\"\u003e\n\u003ctd style=\"padding: 8px; border: 1px solid #ddd;\"\u003e\u003cstrong\u003eMinerals Assessed\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding: 8px; border: 1px solid #ddd;\"\u003eCalcium, Magnesium, Zinc, Selenium, Chromium, Copper, Manganese, Iron (with ferritin)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background: #fff;\"\u003e\n\u003ctd style=\"padding: 8px; border: 1px solid #ddd;\"\u003e\u003cstrong\u003eAntioxidants \/ Specialised\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding: 8px; border: 1px solid #ddd;\"\u003eCoenzyme Q10, Alpha-lipoic acid, Glutathione, Cysteine, Carnitine, Inositol, Choline, Oleic acid\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background: #f9f9f9;\"\u003e\n\u003ctd style=\"padding: 8px; border: 1px solid #ddd;\"\u003e\u003cstrong\u003eSample Required\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding: 8px; border: 1px solid #ddd;\"\u003eBlood draw (venipuncture) at a licensed phlebotomy centre or clinic; Singapore collection points available\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background: #fff;\"\u003e\n\u003ctd style=\"padding: 8px; border: 1px solid #ddd;\"\u003e\u003cstrong\u003eFasting Requirement\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding: 8px; border: 1px solid #ddd;\"\u003e8–12 hours fasting recommended for optimal serum marker accuracy\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background: #f9f9f9;\"\u003e\n\u003ctd style=\"padding: 8px; border: 1px solid #ddd;\"\u003e\u003cstrong\u003eLaboratory Accreditation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding: 8px; border: 1px solid #ddd;\"\u003eISO 15189 accredited clinical laboratory; CLIA-certified analytical facility\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background: #fff;\"\u003e\n\u003ctd style=\"padding: 8px; border: 1px solid #ddd;\"\u003e\u003cstrong\u003eReport Turnaround\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding: 8px; border: 1px solid #ddd;\"\u003e7–14 business days from sample receipt\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background: #f9f9f9;\"\u003e\n\u003ctd style=\"padding: 8px; border: 1px solid #ddd;\"\u003e\u003cstrong\u003eReport Interpretation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding: 8px; border: 1px solid #ddd;\"\u003eClinician-reviewed report with personalised supplementation and dietary recommendations\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background: #fff;\"\u003e\n\u003ctd style=\"padding: 8px; border: 1px solid #ddd;\"\u003e\u003cstrong\u003eRegulatory Status\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding: 8px; border: 1px solid #ddd;\"\u003eClinical laboratory test performed under MOH Healthcare Services Act licensing; not a standalone HSA-registered medical device\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background: #f9f9f9;\"\u003e\n\u003ctd style=\"padding: 8px; border: 1px solid #ddd;\"\u003e\u003cstrong\u003ePrice\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding: 8px; border: 1px solid #ddd;\"\u003eSGD 499 (includes panel, lab processing, and clinical interpretation report)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ch2\u003eClinical Indications\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eChronic fatigue and low energy:\u003c\/strong\u003e Identification of deficiencies in B-complex vitamins, Coenzyme Q10, magnesium, and iron that commonly underlie unexplained fatigue in working-age adults, including burnout presentations evaluated by occupational health physicians.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCardiovascular risk management:\u003c\/strong\u003e Assessment of Vitamin K2 (vascular calcification prevention), CoQ10 (mitochondrial cardiac function), magnesium (arrhythmia risk), homocysteine pathway co-factors (B6, B9, B12) in patients under cardiologist follow-up.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCognitive decline and neuroprotection:\u003c\/strong\u003e Evaluation of B12, folate, Vitamin D, omega-3\/EPA (via lipid subfractions), and antioxidant status in patients presenting with memory complaints, cognitive fatigue, or early neurodegeneration markers.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eImmune system support:\u003c\/strong\u003e Profiling Vitamin D, Vitamin C, Zinc, Selenium, and Vitamin A in patients with recurrent infections, autoimmune conditions, or post-infectious immune reconstitution needs.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePre-conception and fertility:\u003c\/strong\u003e Comprehensive assessment of folate, B12, Vitamin D, iron, zinc, and antioxidant status for women and men planning conception, aligned with MOH pre-conception care guidelines.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCorporate executive and preventive health programmes:\u003c\/strong\u003e Annual or biennial micronutrient baseline for high-functioning executives as part of a comprehensive health optimisation programme alongside metabolic, cardiovascular, and hormonal panels.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eQ: Why is intracellular testing more clinically meaningful than a standard serum micronutrient panel?\u003c\/strong\u003e\u003cbr\u003eA: Serum micronutrient levels reflect transient extracellular concentrations influenced by recent dietary intake, hydration, inflammation (acute-phase reactants suppress serum zinc and selenium during illness), and haemodilution. Intracellular lymphocyte analysis measures the functional nutrient activity within white blood cells — a compartment that reflects cumulative cellular availability over 4–6 months, providing a more accurate assessment of whether nutrients are reaching and being utilised by tissues. A patient may have normal serum Vitamin B6 while simultaneously demonstrating intracellular B6 deficiency affecting neurological function.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eQ: Is this test eligible for Medisave or MediShield Life claims in Singapore?\u003c\/strong\u003e\u003cbr\u003eA: Preventive health screening panels, including micronutrient audits, are generally not claimable under Medisave or MediShield Life unless ordered in the context of an MOH-approved chronic disease management programme. Corporate clients may include this test under employee wellness budgets as a taxable or non-taxable benefit depending on MOH\/IRAS guidelines applicable to their scheme. Patients under the CHAS or Pioneer Generation schemes attending polyclinics should enquire about applicable subsidies for physician-ordered investigations.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eQ: How should results be interpreted and acted upon?\u003c\/strong\u003e\u003cbr\u003eA: The audit report is reviewed by a registered dietitian or physician, who provides a structured interpretation with prioritised intervention recommendations. Supplementation protocols should be tailored to the severity and clinical relevance of each deficiency — not all below-reference values require supplementation, and some deficiencies (e.g., severe Vitamin B12 deficiency) may warrant investigation of aetiology (malabsorption, pernicious anaemia, vegan diet) before supplementation alone is prescribed. Retesting after 3–6 months of targeted intervention is recommended to document response.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eQ: Can the audit be ordered for corporate health screening without a clinician consultation?\u003c\/strong\u003e\u003cbr\u003eA: EMIS+ offers both direct-to-consumer ordering with a post-result clinician consultation and corporate-programme fulfilment with an integrated medical officer review. For institutional or corporate procurement in Singapore, contact EMIS+ to discuss volume pricing, on-site phlebotomy coordination, and anonymous aggregated reporting for corporate health insights. A licensed physician or registered dietitian sign-off is provided for each individual report regardless of the ordering route.\u003c\/p\u003e\n\n\u003cscript type=\"application\/ld+json\"\u003e\n{\n  \"@context\": \"https:\/\/schema.org\",\n  \"@type\": \"FAQPage\",\n  \"mainEntity\": [\n    {\n      \"@type\": \"Question\",\n      \"name\": \"What is Clinical Micronutrient Audit?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Clinical Micronutrient Audit is available from EMIS+ (emis.asia), Singapore's nurse-led medical and wellness supply store. Please refer to the product listing and packaging for its intended use and instructions.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"How do I use Clinical Micronutrient Audit?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Follow the directions provided with the product, or ask your doctor, pharmacist or the EMIS+ team for guidance. Store as directed and use only for its intended purpose.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Is Clinical Micronutrient Audit available without prescription in Singapore?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Yes. Clinical Micronutrient Audit is available from EMIS+ (emis.asia) without a prescription. If you are unsure whether it suits your needs, contact the EMIS+ team or your healthcare provider.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Where can I buy Clinical Micronutrient Audit in Singapore?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Clinical Micronutrient Audit is available from EMIS+ at emis.asia, Singapore's nurse-led medical and wellness supply store, with fast island-wide delivery. Bulk orders for clinics and care facilities are welcome — contact us at emis.asia\/pages\/contact.\"\n      }\n    }\n  ]\n}\n\u003c\/script\u003e","brand":"EMIS +","offers":[{"title":"Default Title","offer_id":43526042779726,"sku":null,"price":499.0,"currency_code":"SGD","in_stock":true}]},{"product_id":"cellular-lipid-matrix","title":"Cellular Lipid Matrix","description":"\u003cdiv style=\"background: #f8f9fa; border-left: 4px solid #0057a8; padding: 12px 16px; margin-bottom: 20px;\" id=\"ai-summary\"\u003e\n\u003cstrong\u003eClinical Summary:\u003c\/strong\u003e The Cellular Lipid Matrix is a comprehensive advanced lipid panel and cardiovascular risk assessment offered by EMIS+ in Singapore. It measures LDL particle number and size, oxidised LDL, lipoprotein(a), apolipoprotein B, inflammatory lipid ratios, and cellular membrane lipid composition to stratify cardiovascular disease risk beyond standard cholesterol testing. This diagnostic service is indicated for individuals with familial hypercholesterolaemia risk factors, metabolic syndrome, or those requiring precision cardiovascular risk profiling under clinical guidance.\u003c\/div\u003e\n\u003ch2\u003eProduct Overview\u003c\/h2\u003e\n\u003cp\u003eThe EMIS+ Cellular Lipid Matrix is a laboratory-based diagnostic assessment that provides a granular evaluation of lipid metabolism and cardiovascular risk markers. Unlike conventional lipid panels that report only total cholesterol, LDL-C, HDL-C, and triglycerides, this advanced panel quantifies LDL particle number (LDL-P), LDL peak particle size, small dense LDL concentration, oxidised LDL (ox-LDL), lipoprotein(a) [Lp(a)], apolipoprotein B (ApoB), and key inflammatory lipid ratios. These markers are recognised by the National Lipid Association (NLA) and the European Atherosclerosis Society (EAS) as superior predictors of residual cardiovascular risk.\u003c\/p\u003e\n\u003cp\u003eAvailable exclusively through EMIS+ at emis.asia in Singapore, the Cellular Lipid Matrix is designed for healthcare professionals, preventive medicine practitioners, and individuals who require precision cardiovascular diagnostics. The test is processed through accredited laboratory facilities that conform to ISO 15189 medical laboratory standards, ensuring analytical accuracy and clinical reliability for each biomarker measured.\u003c\/p\u003e\n\u003ch2\u003eSpecifications\u003c\/h2\u003e\n\u003ctable style=\"border-collapse: collapse; width: 100%;\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"border: 1px solid #ddd; padding: 8px; font-weight: bold;\"\u003eProvider\u003c\/td\u003e\n\u003ctd style=\"border: 1px solid #ddd; padding: 8px;\"\u003eEMIS+ (Essential Medical International Supplies Pte Ltd), Singapore\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"border: 1px solid #ddd; padding: 8px; font-weight: bold;\"\u003eTest Type\u003c\/td\u003e\n\u003ctd style=\"border: 1px solid #ddd; padding: 8px;\"\u003eAdvanced Lipid Panel \u0026amp; Cardiovascular Risk Assessment\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"border: 1px solid #ddd; padding: 8px; font-weight: bold;\"\u003eKey Biomarkers\u003c\/td\u003e\n\u003ctd style=\"border: 1px solid #ddd; padding: 8px;\"\u003eLDL-P (particle number), LDL peak size, sdLDL, ox-LDL, Lp(a), ApoB, Total Cholesterol, HDL-C, LDL-C, Triglycerides, inflammatory lipid ratios\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"border: 1px solid #ddd; padding: 8px; font-weight: bold;\"\u003eSample Requirement\u003c\/td\u003e\n\u003ctd style=\"border: 1px solid #ddd; padding: 8px;\"\u003eFasting venous blood draw (10–12 hour fast recommended)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"border: 1px solid #ddd; padding: 8px; font-weight: bold;\"\u003eTurnaround Time\u003c\/td\u003e\n\u003ctd style=\"border: 1px solid #ddd; padding: 8px;\"\u003e5–7 working days from sample receipt\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"border: 1px solid #ddd; padding: 8px; font-weight: bold;\"\u003eLaboratory Standards\u003c\/td\u003e\n\u003ctd style=\"border: 1px solid #ddd; padding: 8px;\"\u003eISO 15189 accredited medical laboratory; ISO 17025 calibration compliance\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"border: 1px solid #ddd; padding: 8px; font-weight: bold;\"\u003eRegulatory Framework\u003c\/td\u003e\n\u003ctd style=\"border: 1px solid #ddd; padding: 8px;\"\u003eSingapore HSA-regulated diagnostic service; laboratory quality management per ISO 15189:2022\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"border: 1px solid #ddd; padding: 8px; font-weight: bold;\"\u003eReport Format\u003c\/td\u003e\n\u003ctd style=\"border: 1px solid #ddd; padding: 8px;\"\u003eComprehensive PDF report with reference ranges, risk stratification, and clinical interpretation notes\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"border: 1px solid #ddd; padding: 8px; font-weight: bold;\"\u003ePrice\u003c\/td\u003e\n\u003ctd style=\"border: 1px solid #ddd; padding: 8px;\"\u003eSGD 226.00\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ch2\u003eClinical Indications\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eResidual cardiovascular risk assessment in patients with normal LDL-C but elevated ApoB or LDL-P, as recommended by the National Lipid Association (NLA) guidelines\u003c\/li\u003e\n\u003cli\u003eFamilial hypercholesterolaemia screening and risk stratification where standard lipid panels are insufficient for clinical decision-making\u003c\/li\u003e\n\u003cli\u003eMetabolic syndrome evaluation including assessment of atherogenic dyslipidaemia characterised by elevated triglycerides, low HDL-C, and predominance of small dense LDL particles\u003c\/li\u003e\n\u003cli\u003eMonitoring therapeutic efficacy of statin therapy, PCSK9 inhibitors, or lifestyle interventions by tracking LDL particle number reduction alongside LDL-C levels\u003c\/li\u003e\n\u003cli\u003ePreventive cardiovascular health screening for individuals with a family history of premature coronary artery disease or elevated Lp(a) levels, per European Atherosclerosis Society (EAS) consensus recommendations\u003c\/li\u003e\n\u003cli\u003eCellular membrane health assessment for patients presenting with chronic fatigue or inflammatory conditions where lipid peroxidation markers may inform clinical management\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eHow does the Cellular Lipid Matrix differ from a standard lipid panel available at Singapore polyclinics?\u003c\/h3\u003e\n\u003cp\u003eA standard lipid panel measures four markers: total cholesterol, LDL-C, HDL-C, and triglycerides. The Cellular Lipid Matrix extends this to include LDL particle number and size distribution, oxidised LDL, lipoprotein(a), and apolipoprotein B. Research published in the Journal of Clinical Lipidology demonstrates that LDL-P and ApoB are superior predictors of atherosclerotic cardiovascular disease events compared with LDL-C alone, particularly in patients with discordant LDL-C and LDL-P values.\u003c\/p\u003e\n\u003ch3\u003eIs fasting required before the blood draw for this test?\u003c\/h3\u003e\n\u003cp\u003eYes. A 10–12 hour overnight fast is recommended to ensure accurate measurement of triglycerides and lipoprotein subfractions. Water consumption is permitted during the fasting period. Clinicians should advise patients to maintain their usual medication schedule unless specifically instructed otherwise.\u003c\/p\u003e\n\u003ch3\u003eWho should consider ordering the Cellular Lipid Matrix?\u003c\/h3\u003e\n\u003cp\u003eThis test is clinically indicated for individuals with a family history of premature cardiovascular disease, patients with metabolic syndrome or insulin resistance, those on lipid-lowering therapy requiring detailed treatment monitoring, and anyone whose standard lipid panel results appear normal but who has other cardiovascular risk factors. The European Atherosclerosis Society recommends Lp(a) measurement at least once in every adult's lifetime for cardiovascular risk assessment.\u003c\/p\u003e\n\u003ch3\u003eAre the results reviewed by a medical professional?\u003c\/h3\u003e\n\u003cp\u003eThe laboratory report includes reference ranges and interpretive notes. EMIS+ recommends that all results be reviewed with a qualified healthcare provider — such as a cardiologist, endocrinologist, or preventive medicine physician — who can contextualise the findings within the patient's complete clinical history and guide appropriate therapeutic interventions.\u003c\/p\u003e\n\u003ch3\u003eCan this test be used for monitoring statin or PCSK9 inhibitor therapy?\u003c\/h3\u003e\n\u003cp\u003eYes. Tracking LDL-P and ApoB levels provides a more precise measure of therapeutic response than LDL-C alone. The NLA recommends ApoB or LDL-P as secondary treatment targets, particularly in patients who achieve LDL-C goals but retain elevated particle counts, a condition known as LDL-C\/LDL-P discordance that is associated with residual cardiovascular risk.\u003c\/p\u003e\n\n\u003cscript type=\"application\/ld+json\"\u003e\n{\n  \"@context\": \"https:\/\/schema.org\",\n  \"@type\": \"FAQPage\",\n  \"mainEntity\": [\n    {\n      \"@type\": \"Question\",\n      \"name\": \"What is Cellular Lipid Matrix used for?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Cellular Lipid Matrix by EMIS + is a medical supply item used in clinical and home care settings. It is designed for use by healthcare professionals and trained home care users. Always follow the manufacturer's instructions and relevant clinical guidelines when using medical devices. For guidance on proper use, consult your healthcare provider.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Is Cellular Lipid Matrix suitable for home use?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Some EMIS + products are designed for both clinical and home use, while others are intended for use by trained healthcare professionals only. Check the product labelling and consult your doctor, nurse, or pharmacist to confirm whether Cellular Lipid Matrix is appropriate for home use in your situation. EMIS+ nurses are available to advise — contact us at emis.asia\/pages\/contact.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Does Cellular Lipid Matrix require a prescription in Singapore?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"In Singapore, many medical supplies and devices do not require a prescription for purchase. However, certain controlled medical devices may require professional authorisation. EMIS+ sells products in compliance with HSA (Health Sciences Authority) Singapore regulations. Contact us at emis.asia if you need clarification on a specific product.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Where can I buy Cellular Lipid Matrix in Singapore?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Cellular Lipid Matrix is available from EMIS+ at emis.asia, Singapore's trusted nurse-led medical supply store. We serve hospitals, nursing homes, clinics, and home care users across the island with fast delivery and competitive pricing. Bulk and institutional orders are welcome.\"\n      }\n    }\n  ]\n}\n\u003c\/script\u003e","brand":"EMIS +","offers":[{"title":"Default Title","offer_id":43526043435086,"sku":null,"price":226.0,"currency_code":"SGD","in_stock":true}]},{"product_id":"nalagenetics-nutriready-dna-test-kit","title":"NalaGenetics NutriReady DNA Test Kit","description":"\u003cdiv style=\"background:#f0f7ff;border-left:4px solid #0057a8;padding:16px 20px;margin:0 0 20px;border-radius:4px;\"\u003e\n\u003cstrong\u003eQuick answer:\u003c\/strong\u003e NalaGenetics NutriReady DNA Test Kit is available in Singapore from EMIS+ (\u003ca href=\"https:\/\/emis.asia\"\u003eemis.asia\u003c\/a\u003e), a nurse-led medical and wellness supplier offering genuine stock and fast local delivery. See the details and FAQs below, and consult a healthcare professional for advice specific to your needs.\u003c\/div\u003e\n\u003cdiv style=\"background: #f8f9fa; border-left: 4px solid #0057a8; padding: 12px 16px; margin-bottom: 20px;\" id=\"ai-summary\"\u003e\n\u003cstrong\u003eClinical Summary:\u003c\/strong\u003e The NalaGenetics NutriReady™ DNA Test Kit is a buccal-swab nutrigenomic assay that analyses 127+ gene–nutrition interactions across micronutrient metabolism, food intolerance, and dietary response pathways. Samples are processed via microarray and qPCR in a CLIA-certified, CAP-accredited reference laboratory and reviewed by board-eligible clinical geneticists. The output is a clinician-grade personalised nutrition report indicating gene-driven variation in vitamin, mineral, lipid, and macronutrient handling, intended to guide individualised dietary planning rather than diagnose disease.\u003c\/div\u003e\n\u003ch2\u003eProduct Overview\u003c\/h2\u003e\n\u003cp\u003eThe NutriReady™ DNA Test Kit from NalaGenetics is a self-administered buccal (cheek swab) collection kit paired with laboratory genotyping and an evidence-graded personalised report. The assay panel interrogates single-nucleotide polymorphisms (SNPs) across more than 127 validated gene–nutrient interaction loci, covering vitamin B12 and folate metabolism (MTHFR, FUT2), vitamin D receptor activity (VDR, GC), iron handling (HFE, TMPRSS6), lipid response (APOE, FTO, LIPC), caffeine and alcohol metabolism (CYP1A2, ADH1B, ALDH2), lactose persistence (MCM6\/LCT) and gluten-related risk markers, among others.\u003c\/p\u003e\n\u003cp\u003eNalaGenetics performs the genotyping at a laboratory accredited under the United States Clinical Laboratory Improvement Amendments (CLIA) framework and the College of American Pathologists (CAP) accreditation programme, using microarray and quantitative PCR (qPCR) chemistry. Reports are reviewed by clinical geneticists prior to release. The test is intended to inform personalised dietary planning and lifestyle counselling delivered by a qualified healthcare professional; it is not a diagnostic device for disease and does not replace clinical evaluation.\u003c\/p\u003e\n\u003ch2\u003eSpecifications\u003c\/h2\u003e\n\u003ctable style=\"border-collapse: collapse; width: 100%;\" cellspacing=\"0\" cellpadding=\"6\" border=\"1\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003cth align=\"left\"\u003eManufacturer\u003c\/th\u003e\n\u003ctd\u003eNalaGenetics Pte Ltd (Singapore)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth align=\"left\"\u003eProduct\u003c\/th\u003e\n\u003ctd\u003eNutriReady™ DNA Test Kit (personal nutrigenomic profile)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth align=\"left\"\u003eTest category\u003c\/th\u003e\n\u003ctd\u003eDirect-to-consumer nutrigenomic genotyping (predisposition \/ wellness)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth align=\"left\"\u003eSpecimen type\u003c\/th\u003e\n\u003ctd\u003eBuccal swab (non-invasive cheek epithelial cells)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth align=\"left\"\u003eGenotyping technology\u003c\/th\u003e\n\u003ctd\u003eMicroarray + targeted qPCR; bioinformatics pipeline curated against ClinVar, PharmGKB and peer-reviewed gene–nutrient evidence\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth align=\"left\"\u003ePanel size\u003c\/th\u003e\n\u003ctd\u003e127+ gene–nutrition interaction markers (vitamins, minerals, macronutrients, food intolerance, metabolism)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth align=\"left\"\u003eLaboratory accreditation\u003c\/th\u003e\n\u003ctd\u003eCLIA-certified, CAP-accredited reference laboratory\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth align=\"left\"\u003eQuality system\u003c\/th\u003e\n\u003ctd\u003eISO 15189 medical laboratory practice principles applied to processing and reporting\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth align=\"left\"\u003eTurnaround time\u003c\/th\u003e\n\u003ctd\u003eTypically 4–6 weeks from sample receipt\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth align=\"left\"\u003eReport format\u003c\/th\u003e\n\u003ctd\u003eDigital personalised nutrition report (gene-by-trait), with optional clinician consultation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth align=\"left\"\u003eRegulatory positioning\u003c\/th\u003e\n\u003ctd\u003eLifestyle \/ wellness genetic test; not a HSA-registered in-vitro diagnostic medical device for disease diagnosis. Marketed in Singapore for personal nutrition information only.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth align=\"left\"\u003eStorage \/ shelf life\u003c\/th\u003e\n\u003ctd\u003eKit stored at room temperature (15–30°C); collection device sealed until use\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ch2\u003eKey Applications\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003ePersonalised dietary planning informed by gene-driven differences in vitamin and mineral utilisation (e.g., MTHFR-related folate handling, VDR-related vitamin D response).\u003c\/li\u003e\n\u003cli\u003eIdentification of genotype-linked food intolerance markers, including lactose non-persistence (MCM6\/LCT) and caffeine slow-metaboliser status (CYP1A2).\u003c\/li\u003e\n\u003cli\u003eEvidence-led adjustment of macronutrient distribution in weight management programmes (e.g., FTO, APOA2, PPARG).\u003c\/li\u003e\n\u003cli\u003ePre-conception and antenatal nutrition counselling, where folate, B12, choline and iron handling variants are clinically relevant.\u003c\/li\u003e\n\u003cli\u003eAdjunct information for sports and performance nutrition programming (e.g., ACTN3, IL6, COL5A1 where included).\u003c\/li\u003e\n\u003cli\u003ePatient education and behaviour change support in primary-care lifestyle medicine.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eIs NutriReady™ a diagnostic medical device?\u003c\/strong\u003e\u003cbr\u003eNo. NutriReady™ is a wellness \/ nutrigenomic genotyping service. It is not registered with the Singapore Health Sciences Authority (HSA) as an in-vitro diagnostic (IVD) for disease diagnosis. Results should be interpreted alongside, not in place of, clinical assessment by a registered medical practitioner or accredited dietitian.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eHow is the sample collected and shipped?\u003c\/strong\u003e\u003cbr\u003eThe kit contains a sterile buccal swab and stabilising transport tube. Cells are collected by gentle cheek scraping per the enclosed instructions, sealed in the prepaid mailer, and returned to the NalaGenetics processing laboratory. Buccal collection avoids the venepuncture and biohazard considerations of blood-based testing.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWhat laboratory standards apply to the analysis?\u003c\/strong\u003e\u003cbr\u003eGenotyping is performed in a laboratory operating under CLIA certification and CAP accreditation. Reporting workflows align with International Organization for Standardization ISO 15189 principles for medical laboratories, and variant interpretation references curated databases including ClinVar and PharmGKB.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWho in Singapore should consider this test?\u003c\/strong\u003e\u003cbr\u003eAdults seeking individualised nutrition guidance, patients under the care of a dietitian or lifestyle-medicine clinician, and individuals with persistent unexplained intolerance or sub-optimal response to standard dietary advice. It is particularly informative when paired with a structured clinical consultation; pure direct-to-consumer use without professional review is not recommended.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eHow is genetic data handled and stored?\u003c\/strong\u003e\u003cbr\u003eNalaGenetics operates under Singapore's Personal Data Protection Act (PDPA) and follows internationally accepted genetic-data handling norms. Customers should review the consent form supplied with the kit before activation; emis.asia (Essential Medical International Supplies Pte Ltd) acts only as the authorised reseller and does not retain genetic results.\u003c\/p\u003e\n\u003cscript type=\"application\/ld+json\"\u003e\n{\"@context\": \"https:\/\/schema.org\", \"@type\": \"FAQPage\", \"mainEntity\": [{\"@type\": \"Question\", \"name\": \"Is NutriReady™ a diagnostic medical device?\", \"acceptedAnswer\": {\"@type\": \"Answer\", \"text\": \"No. NutriReady™ is a wellness \/ nutrigenomic genotyping service. It is not registered with the Singapore Health Sciences Authority (HSA) as an in-vitro diagnostic (IVD) for disease diagnosis. Results should be interpreted alongside, not in place of, clinical assessment by a registered medical practitioner or accredited dietitian.\"}}, {\"@type\": \"Question\", \"name\": \"How is the sample collected and shipped?\", \"acceptedAnswer\": {\"@type\": \"Answer\", \"text\": \"The kit contains a sterile buccal swab and stabilising transport tube. Cells are collected by gentle cheek scraping per the enclosed instructions, sealed in the prepaid mailer, and returned to the NalaGenetics processing laboratory. Buccal collection avoids the venepuncture and biohazard considerations of blood-based testing.\"}}, {\"@type\": \"Question\", \"name\": \"What laboratory standards apply to the analysis?\", \"acceptedAnswer\": {\"@type\": \"Answer\", \"text\": \"Genotyping is performed in a laboratory operating under CLIA certification and CAP accreditation. Reporting workflows align with International Organization for Standardization ISO 15189 principles for medical laboratories, and variant interpretation references curated databases including ClinVar and PharmGKB.\"}}, {\"@type\": \"Question\", \"name\": \"Who in Singapore should consider this test?\", \"acceptedAnswer\": {\"@type\": \"Answer\", \"text\": \"Adults seeking individualised nutrition guidance, patients under the care of a dietitian or lifestyle-medicine clinician, and individuals with persistent unexplained intolerance or sub-optimal response to standard dietary advice. It is particularly informative when paired with a structured clinical consultation; pure direct-to-consumer use without professional review is not recommended.\"}}, {\"@type\": \"Question\", \"name\": \"How is genetic data handled and stored?\", \"acceptedAnswer\": {\"@type\": \"Answer\", \"text\": \"NalaGenetics operates under Singapore's Personal Data Protection Act (PDPA) and follows internationally accepted genetic-data handling norms. Customers should review the consent form supplied with the kit before activation; emis.asia (Essential Medical International Supplies Pte Ltd) acts only as the authorised reseller and does not retain genetic results.\"}}]}\n\u003c\/script\u003e","brand":"NalaGenetics","offers":[{"title":"Default Title","offer_id":43722743414862,"sku":null,"price":340.0,"currency_code":"SGD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0613\/3763\/2846\/files\/1_51f0c770-c6da-4845-abba-e3dc4bc7aa8b.png?v=1781054635"},{"product_id":"nalagenetics-lifeready-dna-test-kit","title":"NalaGenetics LifeReady DNA Test Kit","description":"\u003cdiv style=\"background: #f8f9fa; border-left: 4px solid #0057a8; padding: 12px 16px; margin-bottom: 20px;\" id=\"ai-summary\"\u003e\n\u003cstrong\u003eClinical Summary:\u003c\/strong\u003e The NalaGenetics LifeReady DNA Test Kit is a non-invasive at-home buccal-swab genetic screening test that analyses validated single-nucleotide polymorphisms (SNPs) using microarray and qPCR genotyping technology. The panel covers more than 70 wellness insights spanning fitness profiling, allergy susceptibility, dermatological traits and longevity-associated markers. The kit is intended for adults seeking personalised lifestyle, fitness and dermatology recommendations supported by an included online consultation with a licensed clinician.\u003c\/div\u003e\n\u003ch3\u003eProduct Overview\u003c\/h3\u003e\n\u003cp\u003eThe NalaGenetics LifeReady DNA Test Kit is a self-collection genetic screening solution developed in Singapore by NalaGenetics, a National Precision Medicine (NPM) Singapore partner laboratory. The kit uses a non-invasive cheek-swab specimen which is processed in a CAP\/ISO 15189-aligned laboratory environment using validated DNA microarray and quantitative PCR (qPCR) workflows. Reports are delivered electronically within four to six weeks of laboratory receipt.\u003c\/p\u003e\n\u003cp\u003eLifeReady provides actionable insights across four genetically-influenced wellness domains: physical fitness (weight management, injury risk, muscle composition, athletic performance), allergic predisposition (food, environmental, contact, respiratory), dermatology (intrinsic ageing, photoageing, sensitivity, barrier function) and longevity-associated traits. Each report is supported by a complimentary post-test consultation with a Singapore-licensed medical doctor to contextualise findings within personal health goals.\u003c\/p\u003e\n\u003ch3\u003eSpecifications\u003c\/h3\u003e\n\u003ctable border=\"1\" style=\"border-collapse: collapse; width: 100%; margin-bottom: 20px;\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"padding: 8px; background: #f1f1f1;\"\u003e\u003cstrong\u003eManufacturer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding: 8px;\"\u003eNalaGenetics Pte Ltd (Singapore)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"padding: 8px; background: #f1f1f1;\"\u003e\u003cstrong\u003eProduct Name\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding: 8px;\"\u003eLifeReady™ DNA Test Kit\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"padding: 8px; background: #f1f1f1;\"\u003e\u003cstrong\u003eSpecimen Type\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding: 8px;\"\u003eBuccal mucosa swab (non-invasive, self-collected)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"padding: 8px; background: #f1f1f1;\"\u003e\u003cstrong\u003eGenotyping Platform\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding: 8px;\"\u003eDNA microarray + targeted qPCR confirmation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"padding: 8px; background: #f1f1f1;\"\u003e\u003cstrong\u003eInsights Covered\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding: 8px;\"\u003e70+ traits across fitness, allergies, skin health and longevity\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"padding: 8px; background: #f1f1f1;\"\u003e\u003cstrong\u003eTurnaround Time\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding: 8px;\"\u003e4–6 weeks from sample receipt\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"padding: 8px; background: #f1f1f1;\"\u003e\u003cstrong\u003eIncluded\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding: 8px;\"\u003eCollection kit, prepaid return mailer, digital report portal access, complimentary doctor teleconsultation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"padding: 8px; background: #f1f1f1;\"\u003e\u003cstrong\u003eQuality Standards\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding: 8px;\"\u003eCAP\/CLIA-aligned workflow, ISO 15189 accreditation framework, ISO 13485 quality system\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"padding: 8px; background: #f1f1f1;\"\u003e\u003cstrong\u003eRegulatory\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding: 8px;\"\u003eMarketed in Singapore as a wellness\/lifestyle DNA test (non-diagnostic). Singapore National Precision Medicine partner.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"padding: 8px; background: #f1f1f1;\"\u003e\u003cstrong\u003eIntended User\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding: 8px;\"\u003eAdults aged 18 and above\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"padding: 8px; background: #f1f1f1;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding: 8px;\"\u003eRoom temperature (15–30°C); use before printed expiry\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ch3\u003eKey Applications\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003ePersonalised exercise programming based on genetic muscle-fibre and recovery profiles\u003c\/li\u003e\n\u003cli\u003ePre-emptive allergen-avoidance counselling, including food and environmental triggers\u003c\/li\u003e\n\u003cli\u003eEvidence-based skincare regimen design accounting for collagen turnover, photoageing risk and barrier integrity\u003c\/li\u003e\n\u003cli\u003eWellness coaching, executive health screening adjuncts and corporate health programmes\u003c\/li\u003e\n\u003cli\u003eLifestyle-medicine clinics integrating genomic data into longevity and preventive-care plans\u003c\/li\u003e\n\u003cli\u003eDermatology and aesthetic clinics requiring genotype-informed treatment selection\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eFrequently Asked Questions\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003eQ: How does buccal-swab DNA testing compare to blood-based genetic testing?\u003c\/strong\u003e\u003cbr\u003eA: For germline SNP genotyping, buccal cells yield equivalent diagnostic-grade DNA to peripheral blood. The Singapore Ministry of Health and the College of American Pathologists both recognise validated buccal-swab workflows for non-invasive germline analysis. Sample integrity is preserved through dry-swab transport in the supplied collection device.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eQ: Is the LifeReady test the same as a clinical pharmacogenomic (PGx) test?\u003c\/strong\u003e\u003cbr\u003eA: No. LifeReady is a wellness and lifestyle screening panel. NalaGenetics offers separate clinical pharmacogenomic panels used in Singapore hospital settings for drug-response prediction; those are ordered through licensed prescribers. LifeReady results should not be used to guide medication decisions.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eQ: How is genetic privacy handled in Singapore?\u003c\/strong\u003e\u003cbr\u003eA: NalaGenetics complies with Singapore's Personal Data Protection Act (PDPA) and the Human Biomedical Research Act (HBRA). Samples are de-identified prior to laboratory processing and customers retain rights to deletion of stored genetic data on written request.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eQ: Can I use this kit if I have already had a stem-cell or bone-marrow transplant?\u003c\/strong\u003e\u003cbr\u003eA: No. Allogeneic haematopoietic stem-cell or bone-marrow transplantation can introduce donor DNA into buccal samples and confound germline results. Patients in this category should consult their treating clinician before testing.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eQ: Where is the kit suitable for procurement in Singapore?\u003c\/strong\u003e\u003cbr\u003eA: Essential Medical International Supplies (EMIS) supplies LifeReady kits to Singapore medical clinics, aesthetic practices, corporate wellness programmes and lifestyle-medicine providers, with delivery across Singapore and B2B invoicing available.\u003c\/p\u003e\n\u003cp\u003e\u003cem\u003eReferences: Singapore Health Sciences Authority (HSA) guidance on direct-to-consumer genetic testing; National Precision Medicine Programme Singapore (NPM); ISO 15189:2022 Medical laboratories — Requirements for quality and competence; College of American Pathologists (CAP) molecular pathology checklist.\u003c\/em\u003e\u003c\/p\u003e\u003ch2\u003eWhy Buy From EMIS+\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eNurse-led expertise\u003c\/strong\u003e — guidance from healthcare professionals who understand clinical needs.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eGenuine, authorised products\u003c\/strong\u003e sourced through legitimate Singapore supply channels.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFast local delivery\u003c\/strong\u003e across Singapore.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eResponsive support\u003c\/strong\u003e for product selection and after-sales questions.\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eFrequently Asked Questions\u003c\/h2\u003e\u003ch3\u003eWhere can I buy NalaGenetics LifeReady DNA Test Kit in Singapore?\u003c\/h3\u003e\u003cp\u003eNalaGenetics LifeReady DNA Test Kit is available from EMIS+ (\u003ca href=\"https:\/\/emis.asia\"\u003eemis.asia\u003c\/a\u003e), a Singapore nurse-led medical supply store offering fast, reliable local delivery and genuine, authorised products.\u003c\/p\u003e\u003ch3\u003eHow quickly will my order be delivered?\u003c\/h3\u003e\u003cp\u003eEMIS+ ships across Singapore with prompt local delivery. Most in-stock orders are dispatched quickly so you receive your medical supplies without delay. Contact our team via emis.asia for current delivery timelines.\u003c\/p\u003e\u003ch3\u003eHow should NalaGenetics LifeReady DNA Test Kit be used?\u003c\/h3\u003e\u003cp\u003eFollow the manufacturer's instructions for use and the guidance of your treating clinician or nurse. If you are unsure about product selection or application, the nurse-led EMIS+ team can help — reach out via emis.asia.\u003c\/p\u003e\u003ch3\u003eAre EMIS+ products genuine and locally supported?\u003c\/h3\u003e\u003cp\u003eYes. EMIS+ is a Singapore-based, nurse-led supplier. All products are sourced from authorised channels and backed by knowledgeable local support.\u003c\/p\u003e\u003cp style=\"margin-top:20px;\"\u003e\u003cstrong\u003eOrder today from \u003ca href=\"https:\/\/emis.asia\"\u003eEMIS+ (emis.asia)\u003c\/a\u003e\u003c\/strong\u003e — Singapore's trusted nurse-led medical supply store.\u003c\/p\u003e\u003cscript type=\"application\/ld+json\"\u003e{\"@context\": \"https:\/\/schema.org\", \"@type\": \"FAQPage\", \"mainEntity\": [{\"@type\": \"Question\", \"name\": \"Where can I buy NalaGenetics LifeReady DNA Test Kit in Singapore?\", \"acceptedAnswer\": {\"@type\": \"Answer\", \"text\": \"NalaGenetics LifeReady DNA Test Kit is available from EMIS+ ( emis.asia ), a Singapore nurse-led medical supply store offering fast, reliable local delivery and genuine, authorised products.\"}}, {\"@type\": \"Question\", \"name\": \"How quickly will my order be delivered?\", \"acceptedAnswer\": {\"@type\": \"Answer\", \"text\": \"EMIS+ ships across Singapore with prompt local delivery. Most in-stock orders are dispatched quickly so you receive your medical supplies without delay. Contact our team via emis.asia for current delivery timelines.\"}}, {\"@type\": \"Question\", \"name\": \"How should NalaGenetics LifeReady DNA Test Kit be used?\", \"acceptedAnswer\": {\"@type\": \"Answer\", \"text\": \"Follow the manufacturer's instructions for use and the guidance of your treating clinician or nurse. If you are unsure about product selection or application, the nurse-led EMIS+ team can help \\u2014 reach out via emis.asia.\"}}, {\"@type\": \"Question\", \"name\": \"Are EMIS+ products genuine and locally supported?\", \"acceptedAnswer\": {\"@type\": \"Answer\", \"text\": \"Yes. EMIS+ is a Singapore-based, nurse-led supplier. All products are sourced from authorised channels and backed by knowledgeable local support.\"}}]}\u003c\/script\u003e","brand":"NalaGenetics","offers":[{"title":"Default Title","offer_id":43722744922190,"sku":null,"price":420.0,"currency_code":"SGD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0613\/3763\/2846\/files\/2_e642e295-ebe8-4400-a7b2-2b9e1d8367b2.png?v=1781054639"}],"url":"https:\/\/www.emis.asia\/collections\/medical-supplies-health-tests-screening.oembed","provider":"EMIS+","version":"1.0","type":"link"}